


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T14:05:12Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12406435" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12406435</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>bmcneph</setSpec>
        
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" article-type="review-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Nephrol</journal-id><journal-id journal-id-type="iso-abbrev">BMC Nephrol</journal-id><journal-id journal-id-type="pmc-domain-id">47</journal-id><journal-id journal-id-type="pmc-domain">bmcneph</journal-id><journal-title-group><journal-title>BMC Nephrology</journal-title></journal-title-group><issn pub-type="epub">1471-2369</issn><publisher><publisher-name>BMC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12406435</article-id><article-id pub-id-type="pmcid-ver">PMC12406435.1</article-id><article-id pub-id-type="pmcaid">12406435</article-id><article-id pub-id-type="pmcaiid">12406435</article-id><article-id pub-id-type="pmid">40898091</article-id><article-id pub-id-type="doi">10.1186/s12882-025-04432-5</article-id><article-id pub-id-type="publisher-id">4432</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Research and advances in mouse models of diabetic nephropathy: a narrative review</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Xie</surname><given-names initials="K">Kang</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ma</surname><given-names initials="Y">Yan</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Din</surname><given-names initials="J">Jingjing</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Jin</surname><given-names initials="Y">Yujie</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhang</surname><given-names initials="S">Siwen</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Liu</surname><given-names initials="S">Shiqiang</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yu</surname><given-names initials="C">Cui</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wu</surname><given-names initials="X">Xu</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Xing</surname><given-names initials="C">Chunyan</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Wang</surname><given-names initials="L">Lizhuo</given-names></name><address><email>20110043@wnmc.edu.cn</email></address><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Gao</surname><given-names initials="J">Jialin</given-names></name><address><email>gaojialin-ktz@wnmc.edu.cn</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/037ejjy86</institution-id><institution-id institution-id-type="GRID">grid.443626.1</institution-id><institution-id institution-id-type="ISNI">0000 0004 1798 4069</institution-id><institution>Department of Endocrinology, Yijishan Hospital, </institution><institution>Wannan Medical College, </institution></institution-wrap>Wuhu, 241000 China </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/037ejjy86</institution-id><institution-id institution-id-type="GRID">grid.443626.1</institution-id><institution-id institution-id-type="ISNI">0000 0004 1798 4069</institution-id><institution>Department of Endocrinology, The Second Affiliated Hospital of Wannan Medical College, </institution></institution-wrap>Wuhu, 241000 China </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/037ejjy86</institution-id><institution-id institution-id-type="GRID">grid.443626.1</institution-id><institution-id institution-id-type="ISNI">0000 0004 1798 4069</institution-id><institution>Endocrinology and Diabetes Research Institute, </institution><institution>Wannan Medical College, </institution></institution-wrap>Wuhu, 241000 China </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/037ejjy86</institution-id><institution-id institution-id-type="GRID">grid.443626.1</institution-id><institution-id institution-id-type="ISNI">0000 0004 1798 4069</institution-id><institution>Anhui Province Key Laboratory of Basic Research and Transformation of Age-Related Diseases, </institution><institution>Wannan Medical College, </institution></institution-wrap>Wuhu, 241000 China </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/037ejjy86</institution-id><institution-id institution-id-type="GRID">grid.443626.1</institution-id><institution-id institution-id-type="ISNI">0000 0004 1798 4069</institution-id><institution>Department of Biochemistry, School of Basic Medicine, </institution><institution>Wannan Medical College, </institution></institution-wrap>Wuhu, 241000 China </aff></contrib-group><pub-date pub-type="epub"><day>2</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>26</volume><issue-id pub-id-type="pmc-issue-id">478197</issue-id><elocation-id>511</elocation-id><history><date date-type="received"><day>9</day><month>5</month><year>2025</year></date><date date-type="accepted"><day>26</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>02</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 10:25:45.023"><day>04</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="12882_2025_Article_4432.pdf"/><abstract id="Abs1" abstract-type="unstructured"><p id="Par1">Diabetic nephropathy (DN) is a leading cause of end-stage renal disease (ESRD), and thus, appropriate animal models are critically needed to investigate its pathogenesis and identify new therapeutic targets. DN mouse models are important tools for studying the mechanisms of DN and exploring therapeutic strategies. Common features of the renal pathology in diabetic patients include thickening of the glomerular basement membrane, mesangial expansion, glomerulosclerosis, tubular injury, and interstitial fibrosis. Although DN mouse models generated through pharmacological or genetic approaches demonstrate comparable renal structural changes, the existing DN mouse models fail to replicate the severity of human DN pathology, underscoring the need for further research to develop more precise DN mouse models. Mouse models with renal pathology that better matches the human condition would provide a key platform for identifying potential therapeutic targets and developing new drugs. This review summarizes the advantages and limitations of various DN mouse models, including pharmacological and dietary induction models, genetically engineered models, spontaneous models generated via genetic modification, and models developed by combined modeling approaches. The goal of this review is to provide valuable insights and guidance for the construction of more comprehensive DN models.</p><p id="Par2"><bold>Clinical trial number</bold> Not applicable.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Diabetic nephropathy</kwd><kwd>Animal model</kwd><kwd>Mice</kwd></kwd-group><funding-group><award-group><funding-source><institution>National Natural Science Foundation of China</institution></funding-source><award-id>82370808</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution>he "Climbing Peak" Training Program for Innovative Technology Team of Yijishan Hospital, Wannan Medical College</institution></funding-source><award-id>PF2019013</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution>the "Peak" Training Program for Scientific Research of Yijishan Hospital, Wannan Medical College</institution></funding-source><award-id>GF2019J07</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution>Major Project Funding from the Anhui Provincial Education Department</institution></funding-source><award-id>2023AH040244</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution>the Clinical Medical Research Transformation Project of Anhui Province</institution></funding-source><award-id>202204295107020067</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution>the Anhui Provincial Health and Medical Research Project-Major Program jointly supported by the Commission and the Province with Provincial Financial Support</institution></funding-source><award-id>2024BAC50001</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; BioMed Central Ltd., part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par3">Diabetic nephropathy (DN) is a common microvascular complication of diabetes and a major cause of end-stage renal disease (ESRD). As the prevalence of diabetes has continually increased, the incidence of DN has also continued to rise, making DN a significant global public health issue [<xref ref-type="bibr" rid="CR1">1</xref>].</p><p id="Par4">Mouse models of DN play a critical role in DN research due to their low cost, ease of handling, and suitability for genetic manipulation [<xref ref-type="bibr" rid="CR2">2</xref>]. Diabetic mouse models allow researchers to observe disease progression, simulate the pathological states of DN in vivo, and further investigate the pathogenesis of DN at the molecular and cellular levels. These models also provide an excellent platform for evaluating the efficacy of novel therapeutics, thereby facilitating the accumulation of substantial data and guidance for future disease prevention and management.</p><p id="Par5">To enhance the development of DN mouse models, the National Institutes of Health established the Animal Models of Diabetic Complications Consortium (AMDCC) in 2001. The AMDCC aims to develop and characterize models for DN and other diabetes complications [<xref ref-type="bibr" rid="CR3">3</xref>]. However, current mouse models used to study DN exhibit significant limitations and fail to fully replicate the pathological features observed in humans. Despite the use of various modeling methods, including induction-based, genetic engineering, and combined approaches, these models only mimic some pathological changes seen in human DN, such as basement membrane thickening, mesangial expansion, and glomerulosclerosis. At present, no single DN mouse model can fully capture the severity of human DN, particularly the advanced stages characterized by segmental mesangiolysis, nodular sclerosis (Kimmelstiel&#8211;Wilson [K&#8211;W] nodules), global glomerulosclerosis, and interstitial fibrosis [<xref ref-type="bibr" rid="CR4">4</xref>].</p><p id="Par6">For example, the streptozotocin (STZ)-induced DN mouse model, which uses an external pharmacological agent to induce diabetes, is simple to establish and easy to handle. However, its renal pathology is limited to glomerular hypertrophy, mesangial expansion, and basement membrane thickening, with occasional glomerulosclerosis and podocyte loss [<xref ref-type="bibr" rid="CR5">5</xref>&#8211;<xref ref-type="bibr" rid="CR8">8</xref>]. This model does not replicate advanced-stage DN features such as the nodular sclerosis observed in humans. Similarly, the db/db mouse model, which develops diabetes spontaneously due to a mutation in the db gene, demonstrates strong modeling potential, exhibiting the renal pathologies of mesangial cell proliferation, mesangial matrix expansion, capillary basement membrane thickening, partial capillary narrowing, tubular epithelial vacuolar degeneration, focal tubular atrophy, and interstitial fibrosis [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. However, DN in the db/db model fails to reach the pathological severity of late-stage human DN [<xref ref-type="bibr" rid="CR11">11</xref>], including global glomerulosclerosis and characteristic K&#8211;W nodules.</p><p id="Par7">Moreover, significant differences in genetic backgrounds, metabolic characteristics, and environmental responses across mouse models further limit the clinical translational potential of research findings. The present article reviews the construction methods and recent advancements of DN mouse models, aiming to provide valuable insights for improving DN model construction.</p></sec><sec id="Sec2"><title>Modeling standards for DN mouse models</title><p id="Par8">The commonly used classification system for human DN is the consensus classification proposed in 2006 by the Research Committee of the Renal Pathology Society [<xref ref-type="bibr" rid="CR12">12</xref>]. Its main categories are presented in Table&#160;<xref rid="Tab1" ref-type="table">1</xref>.</p><p id="Par9">
<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Pathological classification of human DN</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Grade</th><th align="left" colspan="1" rowspan="1">Pathological description</th><th align="left" colspan="1" rowspan="1">Diagnostic criteria</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">I</td><td align="left" colspan="1" rowspan="1">Mild or nonspecific light microscopy changes, confirmed by electron microscopy showing GBM thickening</td><td align="left" colspan="1" rowspan="1">Biopsy does not meet the criteria for grades II, III, or IV; GBM thickness&#8201;&#8805;&#8201;395&#160;nm in females and &#8805;&#8201;430&#160;nm in males aged&#8201;&#8805;&#8201;9 years</td></tr><tr><td align="left" colspan="1" rowspan="1">IIa</td><td align="left" colspan="1" rowspan="1">Mild mesangial expansion</td><td align="left" colspan="1" rowspan="1">Biopsy does not meet the criteria for grades III or IV; mild mesangial expansion observed in &#8805;&#8201;25% of glomeruli</td></tr><tr><td align="left" colspan="1" rowspan="1">IIb</td><td align="left" colspan="1" rowspan="1">Severe mesangial expansion</td><td align="left" colspan="1" rowspan="1">Biopsy does not meet the criteria for grades III or IV; severe mesangial expansion observed in &#8805;&#8201;25% of glomeruli</td></tr><tr><td align="left" colspan="1" rowspan="1">III</td><td align="left" colspan="1" rowspan="1">Nodular sclerosis (Kimmelstiel&#8211;Wilson lesions)</td><td align="left" colspan="1" rowspan="1">Biopsy does not meet the criteria for grade IV; at least one definitive Kimmelstiel&#8211;Wilson lesion</td></tr><tr><td align="left" colspan="1" rowspan="1">IV</td><td align="left" colspan="1" rowspan="1">Advanced diabetic glomerulosclerosis</td><td align="left" colspan="1" rowspan="1">More than 50% of glomeruli affected by sclerosis of grades I&#8211;III</td></tr></tbody></table></table-wrap>
</p><p id="Par10">However, depending on the mouse strain and modeling methods, models exhibit varying degrees of renal pathological changes. To better simulate the pathological state of human DN, the Animal Models of Diabetic Complications Consortium (AMDCC) established ideal criteria for DN mouse models in 2005, which were updated in 2009 [<xref ref-type="bibr" rid="CR3">3</xref>]. These criteria are summarized in Table&#160;<xref rid="Tab2" ref-type="table">2</xref>.</p><p id="Par11">
<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p>Evaluation criteria for diabetic nephropathy in mice</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Criterion</th><th align="left" colspan="1" rowspan="1">Description</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Biochemical</td><td align="left" colspan="1" rowspan="1">(1) A&#8201;&gt;&#8201;50% decline in glomerular filtration rate (GFR) over the animal&#8217;s lifetime</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">(2) A&#8201;&gt;&#8201;10-fold increase in proteinuria compared to age- and sex-matched controls of the same strain</td></tr><tr><td align="left" colspan="1" rowspan="1">Pathological</td><td align="left" colspan="1" rowspan="1">(1) Severe mesangial expansion, mesangiolysis, and nodular sclerosis</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">(2) Any degree of arteriolar hyalinosis</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">(3)&#8201;&gt;&#8201;50% increase in GBM thickness compared to baseline</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">(4) Tubulointerstitial fibrosis</td></tr></tbody></table></table-wrap>
</p><p id="Par12">The AMDCC standards provide a critical framework for modeling the pathological characteristics of human DN. However, existing DN mouse models have yet to fully meet these criteria. Although some models align with these standards, they still fail to adequately replicate the complexity and severity of human DN pathology.</p></sec><sec id="Sec3"><title>Construction of DN mouse models</title><sec id="Sec4"><title>Type 1 DN mouse models</title><sec id="Sec5"><title>Pharmacological induction</title><p id="Par13">
<list list-type="order"><list-item><p id="Par14">Streptozotocin (STZ)</p></list-item></list>
</p><p id="Par15">Streptozotocin (STZ) is an alkylating agent that induces DNA damage and generates reactive oxygen species, leading to the death of pancreatic &#946;-cells [<xref ref-type="bibr" rid="CR2">2</xref>]. This results in insufficient insulin secretion and subsequent hyperglycemia. High doses of STZ can cause nonspecific cytotoxicity and nephrotoxicity, while the use of low doses can reduce these nonspecific effects [<xref ref-type="bibr" rid="CR13">13</xref>], making it one of the most commonly used induction methods.</p><p id="Par16">Studies have shown that, in C57BL/6 male mice, diabetes can be induced by intraperitoneal injection of low-dose STZ (80&#160;mg/kg) for five consecutive days. STZ-induced mice exhibit elevated blood glucose levels at early stages. By 10 weeks, increased urinary protein and urinary albumin-to-creatinine ratio can be detected. Renal pathology reveals basement membrane thickening, glomerular hypertrophy, mesangial expansion, glomerulosclerosis, and reduced podocyte numbers [<xref ref-type="bibr" rid="CR7">7</xref>]. Notably, in addition to persistent hyperglycemia, these mice frequently develop elevated systolic blood pressure, which is a common comorbidity in patients with diabetes. However, serum creatinine levels typically remain unchanged [<xref ref-type="bibr" rid="CR14">14</xref>]. It should be noted that, in this model, renal pathological changes correspond only to class IIa in the human diabetic nephropathy (DN) classification, making it difficult to recapitulate the middle to late stages of the disease. Furthermore, the potential nephrotoxic effects of STZ cannot be completely excluded, which may confound the interpretation of renal injury in this model.</p><p id="Par17">
<list list-type="simple"><list-item><label>(2)</label><p id="Par18">Alloxan (ALX)</p></list-item></list>
</p><p id="Par19">Alloxan (ALX) is a pyrimidine derivative involved in uric acid oxidation. It accumulates in pancreatic cells via uptake through the glucose transporter 2 (GLUT2) protein, reacts with thiols to produce reactive oxygen species, and induces &#946;-cell death. Additionally, ALX inhibits glucokinase activity, further reducing insulin secretion [<xref ref-type="bibr" rid="CR15">15</xref>].</p><p id="Par20">Research indicates that a single intraperitoneal injection of 200&#160;mg/kg ALX in male Swiss albino mice leads to a significant increase in urinary protein as early as 4 weeks of age. By 8 weeks, renal pathological changes are observed, including tubular necrosis, glomerulosclerosis, and ultrastructural alterations such as basement membrane thickening [<xref ref-type="bibr" rid="CR16">16</xref>]. Similarly, another study has shown that after a single tail vein injection of 60&#160;mg/kg of alloxan in male ICR mice for 4 weeks, there was a significant increase in urinary protein levels, accompanied by elevated levels of creatinine and blood lipids. Renal pathology shows thickening of the glomerular basement membrane, glomerular hypertrophy, mesangial matrix proliferation, and glomerulosclerosis [<xref ref-type="bibr" rid="CR17">17</xref>].</p><p id="Par21">Currently, ALX is rarely used for model construction due to its inherent hepatotoxicity and nephrotoxicity [<xref ref-type="bibr" rid="CR18">18</xref>]. Additionally, transient hypoglycemia may occur after injection, which in severe cases can result in the death of mice [<xref ref-type="bibr" rid="CR15">15</xref>].</p></sec><sec id="Sec6"><title>Genetic modification</title><p id="Par22">
<list list-type="order"><list-item><p id="Par23">Non-obese diabetic (NOD) Mice</p></list-item></list>
</p><p id="Par24">Non-obese diabetic (NOD) mice were derived from CTS mice, an inbred strain developed from JCl-ICR cataract mice at the Shionogi Aburai Laboratory in Japan [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR20">20</xref>]. Some CTS mice spontaneously developed polyuria, hyperglycemia, and weight loss, and through selective breeding, a stable NOD mouse model was established [<xref ref-type="bibr" rid="CR21">21</xref>]. Female NOD mice exhibit a higher disease incidence [<xref ref-type="bibr" rid="CR22">22</xref>].</p><p id="Par25">Typically, NOD mice develop pancreatic leukocyte infiltration and inflammation by 4&#8211;5 weeks of age, resulting in &#946;-cell death and reduced insulin secretion [<xref ref-type="bibr" rid="CR23">23</xref>]. NOD mice share significant genetic similarities with human type 1 diabetes, particularly in the major histocompatibility complex (MHC) region [<xref ref-type="bibr" rid="CR24">24</xref>]. The peripheral T-cell deficiency (ptcd) gene on chromosome 7 is involved in T-cell immune dysregulation [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>]. Thus, NOD mice can also serve as models for spontaneous autoimmune diabetes [<xref ref-type="bibr" rid="CR27">27</xref>].</p><p id="Par26">After the onset of diabetes in NOD mice, early renal hypertrophy is observed, and this condition stabilizes by day 20. By day 40, mild mesangial expansion and basement membrane thickening are seen on electron microscopy. Light microscopy shows significant increases in proliferating cell nuclear antigen (PCNA)-positive nuclei and nuclear division in proximal tubules at 10 and 20 days, with increased dense lysosomal bodies in proximal tubules at 40 days [<xref ref-type="bibr" rid="CR19">19</xref>]. In addition, studies have shown that the urinary albumin-to-creatinine ratio (ACR) in NOD mice increases significantly at 4 months of age and continues to rise over time, eventually reaching approximately five times the normal level. However, serum creatinine levels remain unchanged throughout the observation period [<xref ref-type="bibr" rid="CR28">28</xref>].The renal pathological changes in this model are relatively mild, corresponding to grades I or IIa of the human DN classification. Additionally, this model exhibits gender differences and requires long-term insulin administration for survival [<xref ref-type="bibr" rid="CR5">5</xref>].</p><p id="Par27">
<list list-type="simple"><list-item><label>(2)</label><p id="Par28">Ins2Akita Mice</p></list-item></list>
</p><p id="Par29">The Ins2Akita mouse model was first described by Yoshioka et al. in 1997 [<xref ref-type="bibr" rid="CR29">29</xref>]. It carries a mutation in the insulin 2 (Ins2) gene located on the distal region of chromosome 7. This mutation disrupts proper insulin folding, leading to endoplasmic reticulum stress and severe insulin-dependent diabetes [<xref ref-type="bibr" rid="CR29">29</xref>&#8211;<xref ref-type="bibr" rid="CR31">31</xref>].</p><p id="Par30">Research has shown that male mice on the C57BL/6 background exhibit basement membrane thickening at 20 weeks of age. By 40 weeks, mesangial expansion with narrowed capillary lumens and small nodule-like lesions appear. Additionally, podocyte effacement and immunoglobulin A (IgA) deposition are observed [<xref ref-type="bibr" rid="CR32">32</xref>], resembling renal changes seen in some diabetic patients [<xref ref-type="bibr" rid="CR33">33</xref>]. Studies have also demonstrated that, in B6-background mice, systolic blood pressure is elevated, and by 18 weeks of age, a mild increase in urinary albumin-to-creatinine ratio (ACR) as well as elevated blood lipid levels can be observed, while serum creatinine remains unchanged. Furthermore, knockout of the nuclear factor erythroid 2-related factor 2 (Nrf2) gene exacerbates renal inflammation and fibrosis, leading to more pronounced mesangial and distal tubular expansion by 40 weeks of age [<xref ref-type="bibr" rid="CR34">34</xref>]. Although genetic modification in this model can exacerbate renal lesions, it still fails to reproduce the advanced pathological changes seen in late-stage human diabetic nephropathy. In addition, there are sex differences in disease severity, with male mice displaying more prominent renal alterations [<xref ref-type="bibr" rid="CR32">32</xref>]. </p><p id="Par31">
<list list-type="simple"><list-item><label>(3)</label><p id="Par32">OVE26-FVB Mice</p></list-item></list>
</p><p id="Par33">The OVE26-FVB mouse model is generated on the FVB background through the introduction of a calmodulin gene regulated by a rat insulin II promoter. This leads to calmodulin overexpression, which damages pancreatic &#946;-cells and induces diabetes. The model exhibits rapid diabetes progression and can survive for just over a year under sustained hyperglycemia [<xref ref-type="bibr" rid="CR35">35</xref>].</p><p id="Par34">In this model, the albumin excretion rate is significantly elevated as early as 2 months of age and continues to increase markedly with age. By 9 months, severe proteinuria develops, with average albumin excretion exceeding 15&#160;mg/24&#160;h. Notably, diastolic blood pressure is increased at 3 months, and both diastolic and systolic blood pressure are significantly elevated by 8 months of age. Between 2 and 5 months, renal weight doubles, and renal pathology reveals glomerular enlargement and mesangial matrix expansion, accompanied by tubulointerstitial fibrosis and basement membrane thickening. Light microscopy demonstrates glomerulosclerosis resembling Kimmelstiel&#8211;Wilson (K&#8211;W) lesions [<xref ref-type="bibr" rid="CR36">36</xref>], along with podocyte fusion and reduced podocyte numbers [<xref ref-type="bibr" rid="CR37">37</xref>]. This model exhibits hallmark features similar to human DN, with pathological changes approximating grade III of the human DN classification. However, the OVE26-FVB mouse model still falls short of replicating the full severity observed in human DN. Although both male and female OVE26 mice develop comparable diabetes, female mice exhibit more severe renal injury [<xref ref-type="bibr" rid="CR38">38</xref>].</p></sec><sec id="Sec7"><title>Combined modeling</title><p id="Par35">
<list list-type="order"><list-item><p id="Par36">STZ&#8201;+&#8201;endothelial nitric oxide synthase (eNOS) Knockout</p></list-item></list>
</p><p id="Par37">Endothelial injury is a hallmark of diabetes and contributes to microvascular complications. Nitric oxide (NO), synthesized by endothelial cells, is a critical regulator of vascular permeability and is produced under the control of endothelial nitric oxide synthase (eNOS). Changes in eNOS activity are believed to be associated with the progression of advanced DN [<xref ref-type="bibr" rid="CR3">3</xref>].</p><p id="Par38">Studies have shown that in STZ-induced type 1 diabetic mice with eNOS knockout on the C57BL/6J background, there is a marked increase in urinary protein at 3 months of age, which becomes even more pronounced by 5 months. Renal enlargement, mesangial expansion, glomerulosclerosis, and basement membrane thickening can be observed by 3 months of age, along with the formation of microaneurysms. Between 3 and 5 months, Kimmelstiel&#8211;Wilson (K&#8211;W)-like nodules and fibrin deposition occasionally appear [<xref ref-type="bibr" rid="CR39">39</xref>].In addition, studies have shown that these mice develop significant hypertension and elevated serum creatinine levels after 12 weeks [<xref ref-type="bibr" rid="CR14">14</xref>]. However, eNOS knockout in this model results in hypercoagulability and low survival rates [<xref ref-type="bibr" rid="CR40">40</xref>]. Additionally, the STZ dose significantly influences the extent of renal injury in this model [<xref ref-type="bibr" rid="CR41">41</xref>].</p><p id="Par39">
<list list-type="simple"><list-item><label>(2)</label><p id="Par40">STZ&#8201;+&#8201;Unilateral Nephrectomy (UNx)</p></list-item></list>
</p><p id="Par41">Unilateral nephrectomy (UNx) was first introduced by Steffes et al. in 1978 [<xref ref-type="bibr" rid="CR42">42</xref>]. They found that STZ-induced diabetes in Sprague&#8211;Dawley rats results in exacerbated renal damage following UNx [<xref ref-type="bibr" rid="CR42">42</xref>]. This method has also been applied in CD-1 mice [<xref ref-type="bibr" rid="CR43">43</xref>]. These studies demonstrated that STZ&#8201;+&#8201;UNx accelerates and worsens renal lesions.</p><p id="Par42">In B6-background mice, five consecutive days of intraperitoneal injection of STZ (50&#160;mg/kg) combined with UNx induces a type 1 diabetic nephropathy (DN) mouse model. After 12 weeks, these mice exhibit a significant increase in urinary protein, whereas serum creatinine levels remain unchanged. Renal histopathology reveals glomerular hypertrophy, basement membrane thickening, mesangial matrix expansion, early glomerulosclerosis, upregulation of profibrotic markers, tubular injury, and tubulointerstitial fibrosis [<xref ref-type="bibr" rid="CR44">44</xref>]. Compared with STZ induction alone, this model presents with more severe renal lesions; however, it does not show changes in blood pressure and still fails to recapitulate human-like nodular sclerosis [<xref ref-type="bibr" rid="CR45">45</xref>]. Moreover, the surgical procedure carries the risks of bleeding and infection, reducing mouse survival rates [<xref ref-type="bibr" rid="CR46">46</xref>].</p></sec></sec><sec id="Sec8"><title>Type 2 DN mouse models</title><sec id="Sec9"><title>Diet-induced models</title><sec id="Sec10"><title>High-fat diet (HFD)</title><p id="Par43">Obesity is a complex chronic condition involving long-term pathophysiological changes and adaptations [<xref ref-type="bibr" rid="CR47">47</xref>]. Obese individuals often experience insulin resistance, a primary cause of type 2 diabetes, closely associated with unhealthy dietary habits. Feeding mice a high-fat diet (HFD) induces weight gain, insulin resistance, and impaired &#946;-cell function, effectively mimicking the pathogenesis of human type 2 diabetes. Additionally, HFD feeding increases inflammatory infiltration in the kidneys, leading to tissue damage and necrosis, which are critical factors in the progression of DN [<xref ref-type="bibr" rid="CR48">48</xref>].</p><p id="Par44">Research has shown that in C57BL/6 mice, an increase in the urinary albumin-to-creatinine ratio (ACR) can be detected after 4 weeks of high-fat diet (HFD) feeding, although this upward trend is not pronounced over time. After 12 weeks of HFD, renal pathological changes become evident, including glomerular hypertrophy, basement membrane thickening, mesangial expansion, and glomerulosclerosis, accompanied by dyslipidemia, vascular remodeling, and elevated systolic blood pressure [<xref ref-type="bibr" rid="CR49">49</xref>]. This model is simple to establish and widely used. However, responses to HFD feeding vary significantly across mouse strains and sexes [<xref ref-type="bibr" rid="CR50">50</xref>]. Furthermore, the long and inconsistent modeling timeline limits the ability of this model to replicate mid- to late-stage DN changes, with pathology resembling grade IIa of the human DN classification.</p></sec></sec><sec id="Sec11"><title>Genetically modified models</title><p id="Par45">
<list list-type="order"><list-item><p id="Par46">New Zealand Obese (NZO) Mice</p></list-item></list>
</p><p id="Par47">NZO mice are a polygenic model of type 2 diabetes. Initially introduced to New Zealand from London in 1930, this strain was developed by Marianne et al. and confirmed to exhibit metabolic abnormalities in 1953 [<xref ref-type="bibr" rid="CR51">51</xref>, <xref ref-type="bibr" rid="CR52">52</xref>]. Male NZO mice show significantly elevated systolic blood pressure at 6 weeks and develop early-onset obesity, insulin resistance, and glucose-lipid metabolic disorders between 12 and 22 weeks, whereas females do not exhibit these traits [<xref ref-type="bibr" rid="CR53">53</xref>, <xref ref-type="bibr" rid="CR54">54</xref>].</p><p id="Par48">After 6 months, the renal pathological changes in NZO mice include glomerular hyperplasia, mild basement membrane thickening, glomerulosclerosis, and IgM deposition [<xref ref-type="bibr" rid="CR55">55</xref>]. Additionally, studies have found that after unilateral ureteral obstruction in NZO mice, urinary protein and urinary albumin-to-creatinine ratio remain at low levels and do not show significant changes, and serum creatinine levels also remain unchanged. However, this intervention can accelerate and exacerbate renal lesions [<xref ref-type="bibr" rid="CR56">56</xref>]. Nevertheless, this model still does not replicate hallmark features of human DN, such as nodular sclerosis. Moreover, the construction of the NZO mouse model involves multiple genetic factors, and the model exhibits gender differences and relatively mild renal pathological changes.</p><p id="Par49">
<list list-type="simple"><list-item><label>(2)</label><p id="Par50">db/db Mice</p></list-item></list>
</p><p id="Par51">The db/db mouse was first identified in 1966 at the Jackson Laboratory. It carries a G-to-T mutation in the db gene on chromosome 4, resulting in an abnormal leptin receptor, which leads to obesity, insulin resistance, and hyperglycemia [<xref ref-type="bibr" rid="CR57">57</xref>, <xref ref-type="bibr" rid="CR58">58</xref>].</p><p id="Par52">Studies have shown that male C57BLKS/J-db/db mice exhibit rapid disease progression, developing hyperglycemia as early as 5&#8211;8 weeks of age. By 10 weeks, these mice display elevated serum creatinine levels, a reduced glomerular filtration rate (GFR), and marked proteinuria. At 16&#8211;18 weeks of age, mesangial expansion and increased matrix deposition extend into normal capillary areas, closely resembling the pathological changes observed in human diabetic nephropathy [<xref ref-type="bibr" rid="CR59">59</xref>].</p><p id="Par53">Combination of the db/db model with eNOS knockout exacerbates renal damage. Studies have found that in this combined model, basement membrane thickening becomes evident by 16 weeks of age. By 26 weeks, there is a significant increase in the urinary albumin-to-creatinine ratio, a decline in glomerular filtration rate (GFR), elevated serum creatinine, and increased blood pressure.</p><p id="Par54">Renal pathology reveals arteriolar hyalinosis, mesangial expansion, early glomerulosclerosis, mild interstitial fibrosis, and a reduction in podocyte number. Additionally, upregulation of oxidative stress, inflammatory mediators, and profibrotic factors further aggravates renal injury [<xref ref-type="bibr" rid="CR60">60</xref>, <xref ref-type="bibr" rid="CR61">61</xref>].</p><p id="Par55">While the combined db/db and eNOS knockout model has been the most commonly used model for studying type 2 DN, these mice are highly sensitive to hyperglycemic toxicity and require insulin support for survival [<xref ref-type="bibr" rid="CR58">58</xref>]. Although eNOS knockout aggravates renal lesions, it still fails to replicate the full severity observed in human DN. In addition, eNOS deficiency leads to hypercoagulability and is associated with reduced survival rates in mice [<xref ref-type="bibr" rid="CR40">40</xref>]. </p><p id="Par56">
<list list-type="simple"><list-item><label>(3)</label><p id="Par57">ob/ob Mice</p></list-item></list>
</p><p id="Par58">ob/ob mice were first identified by Ingalls et al. in 1949 and have a mutation in the ob gene on chromosome 6 that causes leptin deficiency. This autosomal recessive mutation disrupts leptin signaling pathways, leading to obesity, insulin resistance, and eventually hyperglycemia [<xref ref-type="bibr" rid="CR62">62</xref>&#8211;<xref ref-type="bibr" rid="CR64">64</xref>].</p><p id="Par59">On the Black and Tan Brachyury (BTBR) background, ob/ob mice exhibit severe renal changes. The BTBR strain, developed by L.C. Dunn through inbreeding T-mutation carriers, is highly susceptible to diabetes [<xref ref-type="bibr" rid="CR65">65</xref>, <xref ref-type="bibr" rid="CR66">66</xref>]. Research has shown that these mice develop insulin resistance and hyperglycemia by 4 weeks of age, followed by the onset of proteinuria. At 8 weeks, both urinary protein levels and the urinary albumin-to-creatinine ratio increase significantly, accompanied by glomerular hypertrophy and mesangial matrix accumulation. By 20 weeks, the urinary albumin-to-creatinine ratio reaches its peak and is accompanied by hyperlipidemia, whereas serum creatinine levels remain unchanged throughout the observation period. Notably, these mice do not develop arteriosclerosis or hypertension. At 22 weeks, the basement membrane thickness increases by approximately 20%, mesangial matrix deposition exceeds 50%, and advanced DN features&#8212;including glomerulosclerosis, mesangiolysis, and mild interstitial fibrosis&#8212;become apparent. In addition, early and persistent podocyte loss and fusion are also observed [<xref ref-type="bibr" rid="CR67">67</xref>].</p><p id="Par60">ob/ob mice provide a comprehensive model of type 2 DN, with progressive proteinuria and glomerular histopathological features closely resembling human DN [<xref ref-type="bibr" rid="CR68">68</xref>]. However, these mice are difficult to breed, and high mortality rates after 24 weeks limit their utility in modeling advanced renal disease [<xref ref-type="bibr" rid="CR69">69</xref>].</p><p id="Par61">
<list list-type="simple"><list-item><label>(4)</label><p id="Par62">KK-Ay Mice</p></list-item></list>
</p><p id="Par63">The KK-Ay mouse model was developed in 1969 by Nishimura et al. through the introduction of the yellow obesity gene (Ay allele) in KK/Ta mice. KK-Ay mice exhibit more severe obesity, insulin resistance, hyperglycemia, and proteinuria than KK/Ta mice [<xref ref-type="bibr" rid="CR70">70</xref>].</p><p id="Par64">The KK-Ay mice gain weight after 8 weeks of age and exhibit a progressively increasing urine albumin-to-creatinine ratio (ACR). After 12 weeks, there are significant increases in urinary protein-to-creatinine ratio, blood glucose, glycated hemoglobin, and other metabolic indicators. By 20 weeks, the urinary albumin-to-creatinine ratio continues to rise and then plateaus; however, no changes in blood pressure are observed throughout the study period. Renal histopathology at this stage demonstrates basement membrane thickening, diffuse and moderate-to-severe mesangial matrix expansion with mesangial cell proliferation, segmental sclerosis, nodular mesangial lesions, and a reduction in podocyte number [<xref ref-type="bibr" rid="CR71">71</xref>]. Additionally, inflammation contributes to renal injury in KK-Ay mice [<xref ref-type="bibr" rid="CR72">72</xref>].</p><p id="Par65">Although proteinuria worsens with age in this model, it does not result in renal insufficiency or kidney failure [<xref ref-type="bibr" rid="CR11">11</xref>]. Moreover, the renal pathological changes fail to reach the severity observed in human DN.</p></sec><sec id="Sec12"><title>Combined modeling</title><p id="Par66">
<list list-type="order"><list-item><p id="Par67">HFD&#8201;+&#8201;STZ</p></list-item></list>
</p><p id="Par68">The HFD&#8201;+&#8201;STZ combined modeling approach first induces insulin resistance through HFD feeding, and then low-dose STZ is injected to impair insulin secretion and cause hyperglycemia, ultimately leading to structural and functional kidney abnormalities [<xref ref-type="bibr" rid="CR73">73</xref>, <xref ref-type="bibr" rid="CR74">74</xref>].</p><p id="Par69">In mice on the B6 background, a diabetic nephropathy (DN) model is established by feeding a high-fat diet (HFD) for 4 weeks followed by low-dose STZ (50&#160;mg/kg) intraperitoneal injections for 1 week. After 5 weeks, a significant increase in urinary albumin is observed, accompanied by elevated serum creatinine and hyperlipidemia. Renal pathology reveals glomerular basement membrane thickening, mesangial cell proliferation, and mesangial matrix expansion [<xref ref-type="bibr" rid="CR75">75</xref>]. Additionally, lipid changes exacerbate renal lipotoxicity, promoting DN progression [<xref ref-type="bibr" rid="CR76">76</xref>]. This method is simple and time-efficient; however, the STZ dose has a significant impact on the model&#8217;s success, with high doses potentially causing death and low doses potentially failing to induce the model [<xref ref-type="bibr" rid="CR77">77</xref>].</p><p id="Par70">
<list list-type="simple"><list-item><label>(2)</label><p id="Par71">db/db Mice&#8201;+&#8201;Unilateral renal artery stenosis (RAS)</p></list-item></list>
</p><p id="Par72">The construction of this model involves surgically inducing unilateral renal artery stenosis (RAS) in mice, which leads to renovascular hypertension and exacerbation of renal lesions. Studies have shown that in C57BLKS-db/db mice, a significant increase in urinary protein is observed as early as 1 week after unilateral RAS surgery. By 2 weeks post-surgery, proteinuria further increases, and the contralateral kidney develops diffuse mesangial sclerosis and interstitial fibrosis, accompanied by inflammatory cell infiltration. By 4 weeks, proteinuria peaks and persists thereafter. By 6 weeks post-surgery, the contralateral kidney exhibits mesangial expansion, basement membrane thickening, and podocyte fusion [<xref ref-type="bibr" rid="CR78">78</xref>].</p><p id="Par73">While this model simulates hypertension-induced exacerbation of renal lesions, blood pressure increases within one week after surgery and remains elevated thereafter, accompanied by weight gain. However, the risk of aortic bleeding and dissection is increased, leading to a high incidence of sudden death and low survival rates in mice [<xref ref-type="bibr" rid="CR79">79</xref>].</p></sec></sec></sec><sec id="Sec13"><title>Differences between DN mouse models and human DN</title><p id="Par74">DN is a late-stage complication of diabetes that typically manifests clinically as persistent proteinuria, generally appearing after 10 years of diabetes progression [<xref ref-type="bibr" rid="CR80">80</xref>] and accompanied by a sustained decline in GFR, eventually leading to renal failure. Renal changes in DN primarily reflect the progression of glomerular lesions, which evolve from basement membrane thickening to mesangial expansion, K&#8211;W lesions, and global glomerulosclerosis [<xref ref-type="bibr" rid="CR12">12</xref>].</p><p id="Par75">In various mouse models, some pathological features similar to those of human DN are observed, but the severity of these changes is often limited (see Table&#160;<xref rid="Tab3" ref-type="table">3</xref>). Additionally, the short lifespan of mice hinders the ability of mouse models to sustain a prolonged diabetic state or mimic the persistent decline in GFR seen in human DN.</p><p id="Par76">The pathogenesis of human DN involves a complex interplay of multiple factors, including hyperglycemia, hypertension, inflammation, oxidative stress, and genetic predisposition. These factors are difficult to fully replicate in mouse models. Furthermore, the phenotypes of mouse models may be influenced by environmental factors, which can alter disease presentation and, in some cases, promote genetic adaptation [<xref ref-type="bibr" rid="CR81">81</xref>].</p><p id="Par77">
<table-wrap id="Tab3" position="float" orientation="portrait"><label>Table 3</label><caption><p>Differences between human DN and mouse DN models</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Type</th><th align="left" colspan="1" rowspan="1">Model</th><th align="left" colspan="1" rowspan="1">Strain</th><th align="left" colspan="1" rowspan="1">Mechanism</th><th align="left" colspan="1" rowspan="1">Metabolic Disorder</th><th align="left" colspan="1" rowspan="1">Scr</th><th align="left" colspan="1" rowspan="1">UACR</th><th align="left" colspan="1" rowspan="1">Alb</th><th align="left" colspan="1" rowspan="1">GBM thickening</th><th align="left" colspan="1" rowspan="1">ME</th><th align="left" colspan="1" rowspan="1">GS</th><th align="left" colspan="1" rowspan="1">IF</th><th align="left" colspan="1" rowspan="1">PL</th><th align="left" colspan="1" rowspan="1">ObsT</th><th align="left" colspan="1" rowspan="1">Refs.</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Type 1 Diabetes</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Pharmacological induction</td><td align="left" colspan="1" rowspan="1">STZ</td><td align="left" colspan="1" rowspan="1">C57BL/6J</td><td align="left" colspan="1" rowspan="1">&#946;-cell apoptosis</td><td align="left" colspan="1" rowspan="1">Hyperglycemia; Hypertension</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">+</td><td align="left" colspan="1" rowspan="1">+</td><td align="left" colspan="1" rowspan="1">+</td><td align="left" colspan="1" rowspan="1">+</td><td align="left" colspan="1" rowspan="1">+</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">+</td><td align="left" colspan="1" rowspan="1">10weeks</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR5">5</xref>&#8211;<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">ALX</td><td align="left" colspan="1" rowspan="1">ICR</td><td align="left" colspan="1" rowspan="1">&#946;-cell apoptosis</td><td align="left" colspan="1" rowspan="1">Hyperglycemia; Hypertension; Transient Hypoglycemia</td><td align="left" colspan="1" rowspan="1">+</td><td align="left" colspan="1" rowspan="1">++</td><td align="left" colspan="1" rowspan="1">++</td><td align="left" colspan="1" rowspan="1">+</td><td align="left" colspan="1" rowspan="1">+</td><td align="left" colspan="1" rowspan="1">+</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">4weeks</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR15">15</xref>&#8211;<xref ref-type="bibr" rid="CR17">17</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Genetic modification</td><td align="left" colspan="1" rowspan="1">NOD</td><td align="left" colspan="1" rowspan="1">ICR</td><td align="left" colspan="1" rowspan="1">Multi-gene immune response</td><td align="left" colspan="1" rowspan="1">Hyperglycemia</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">++</td><td align="left" colspan="1" rowspan="1">++</td><td align="left" colspan="1" rowspan="1">+</td><td align="left" colspan="1" rowspan="1">+</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">40days</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR28">28</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Ins2Akita</td><td align="left" colspan="1" rowspan="1">C57BL/6J</td><td align="left" colspan="1" rowspan="1">Insulin 2 gene mutation</td><td align="left" colspan="1" rowspan="1">Hyperglycemia; Hypertension; Dyslipidemia</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">+</td><td align="left" colspan="1" rowspan="1">+</td><td align="left" colspan="1" rowspan="1">+</td><td align="left" colspan="1" rowspan="1">++</td><td align="left" colspan="1" rowspan="1">+</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">+</td><td align="left" colspan="1" rowspan="1">20weeks</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR29">29</xref>&#8211;<xref ref-type="bibr" rid="CR32">32</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">OVE26-FVB</td><td align="left" colspan="1" rowspan="1">FVB</td><td align="left" colspan="1" rowspan="1">Calmodulin gene overexpression</td><td align="left" colspan="1" rowspan="1">Hyperglycemia; Hypertension</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">++++</td><td align="left" colspan="1" rowspan="1">++++</td><td align="left" colspan="1" rowspan="1">+</td><td align="left" colspan="1" rowspan="1">+++</td><td align="left" colspan="1" rowspan="1">++</td><td align="left" colspan="1" rowspan="1">+</td><td align="left" colspan="1" rowspan="1">+</td><td align="left" colspan="1" rowspan="1">2months</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR35">35</xref>&#8211;<xref ref-type="bibr" rid="CR37">37</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Combined models</td><td align="left" colspan="1" rowspan="1">STZ&#8201;+&#8201;eNOS-/-</td><td align="left" colspan="1" rowspan="1">C57BL/6J</td><td align="left" colspan="1" rowspan="1">&#946;-cell apoptosis&#8201;+&#8201;loss of eNOS</td><td align="left" colspan="1" rowspan="1">Hyperglycemia; Hypertension</td><td align="left" colspan="1" rowspan="1">+</td><td align="left" colspan="1" rowspan="1">+</td><td align="left" colspan="1" rowspan="1">+++</td><td align="left" colspan="1" rowspan="1">+</td><td align="left" colspan="1" rowspan="1">++</td><td align="left" colspan="1" rowspan="1">++</td><td align="left" colspan="1" rowspan="1">+</td><td align="left" colspan="1" rowspan="1">+</td><td align="left" colspan="1" rowspan="1">5months</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR39">39</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">STZ&#8201;+&#8201;UNx</td><td align="left" colspan="1" rowspan="1">C57BL/6J</td><td align="left" colspan="1" rowspan="1">&#946;-cell apoptosis&#8201;+&#8201;surgical renal damage</td><td align="left" colspan="1" rowspan="1">Hyperglycemia</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">++</td><td align="left" colspan="1" rowspan="1">++</td><td align="left" colspan="1" rowspan="1">+</td><td align="left" colspan="1" rowspan="1">+</td><td align="left" colspan="1" rowspan="1">+</td><td align="left" colspan="1" rowspan="1">+</td><td align="left" colspan="1" rowspan="1">+</td><td align="left" colspan="1" rowspan="1">12weeks</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR44">44</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Type 2 Diabetes</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Diet-induced</td><td align="left" colspan="1" rowspan="1">HFD</td><td align="left" colspan="1" rowspan="1">C57BL/6J</td><td align="left" colspan="1" rowspan="1">Insulin resistance</td><td align="left" colspan="1" rowspan="1">Obesity; Insulin Resistance; Hyperglycemia; Hypertension; Dyslipidemia</td><td align="left" colspan="1" rowspan="1">+</td><td align="left" colspan="1" rowspan="1">+</td><td align="left" colspan="1" rowspan="1">+</td><td align="left" colspan="1" rowspan="1">+</td><td align="left" colspan="1" rowspan="1">+</td><td align="left" colspan="1" rowspan="1">+</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">12weeks</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR49">49</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Genetic modification</td><td align="left" colspan="1" rowspan="1">NZO</td><td align="left" colspan="1" rowspan="1">&#8212;</td><td align="left" colspan="1" rowspan="1">Polygenic inheritance</td><td align="left" colspan="1" rowspan="1">Obesity; Insulin Resistance; Hyperglycemia; Hypertension; Dyslipidemia</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">+</td><td align="left" colspan="1" rowspan="1">+</td><td align="left" colspan="1" rowspan="1">+</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">6Months</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR52">52</xref>, <xref ref-type="bibr" rid="CR55">55</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">db/db</td><td align="left" colspan="1" rowspan="1">C57BLKS/J</td><td align="left" colspan="1" rowspan="1">db gene mutation</td><td align="left" colspan="1" rowspan="1">Obesity; Insulin Resistance; Hyperglycemia</td><td align="left" colspan="1" rowspan="1">+</td><td align="left" colspan="1" rowspan="1">+</td><td align="left" colspan="1" rowspan="1">++</td><td align="left" colspan="1" rowspan="1">+</td><td align="left" colspan="1" rowspan="1">+</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">16weeks</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR58">58</xref>, <xref ref-type="bibr" rid="CR59">59</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">db/db&#8201;+&#8201;eNOS-/-</td><td align="left" colspan="1" rowspan="1">C57BLKS/J</td><td align="left" colspan="1" rowspan="1">db gene mutation and eNOS loss</td><td align="left" colspan="1" rowspan="1">Obesity; Insulin Resistance; Hyperglycemia; Hypertension</td><td align="left" colspan="1" rowspan="1">+</td><td align="left" colspan="1" rowspan="1">+++</td><td align="left" colspan="1" rowspan="1">+++</td><td align="left" colspan="1" rowspan="1">++</td><td align="left" colspan="1" rowspan="1">+++</td><td align="left" colspan="1" rowspan="1">+</td><td align="left" colspan="1" rowspan="1">+</td><td align="left" colspan="1" rowspan="1">+</td><td align="left" colspan="1" rowspan="1">16weeks</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR58">58</xref>, <xref ref-type="bibr" rid="CR60">60</xref>, <xref ref-type="bibr" rid="CR61">61</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">ob/ob</td><td align="left" colspan="1" rowspan="1">BTBR</td><td align="left" colspan="1" rowspan="1">ob gene mutation</td><td align="left" colspan="1" rowspan="1">Obesity; Insulin Resistance; Hyperglycemia; Dyslipidemia</td><td align="left" colspan="1" rowspan="1">+</td><td align="left" colspan="1" rowspan="1">++++</td><td align="left" colspan="1" rowspan="1">+++</td><td align="left" colspan="1" rowspan="1">++</td><td align="left" colspan="1" rowspan="1">+++</td><td align="left" colspan="1" rowspan="1">++</td><td align="left" colspan="1" rowspan="1">+</td><td align="left" colspan="1" rowspan="1">+</td><td align="left" colspan="1" rowspan="1">8weeks</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR62">62</xref>&#8211;<xref ref-type="bibr" rid="CR64">64</xref>, <xref ref-type="bibr" rid="CR67">67</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">KK-Ay</td><td align="left" colspan="1" rowspan="1">KK</td><td align="left" colspan="1" rowspan="1">Ay allele transfer</td><td align="left" colspan="1" rowspan="1">Obesity; Insulin Resistance; Hyperglycemia</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">+++</td><td align="left" colspan="1" rowspan="1">+++</td><td align="left" colspan="1" rowspan="1">+</td><td align="left" colspan="1" rowspan="1">+</td><td align="left" colspan="1" rowspan="1">+</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">+</td><td align="left" colspan="1" rowspan="1">20weeks</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR70">70</xref>, <xref ref-type="bibr" rid="CR71">71</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Combined models</td><td align="left" colspan="1" rowspan="1">HFD&#8201;+&#8201;STZ</td><td align="left" colspan="1" rowspan="1">C57BL/6J</td><td align="left" colspan="1" rowspan="1">Insulin resistance&#8201;+&#8201;&#946;-cell apoptosis</td><td align="left" colspan="1" rowspan="1">Insulin Resistance; Hyperglycemia; Dyslipidemia</td><td align="left" colspan="1" rowspan="1">+</td><td align="left" colspan="1" rowspan="1">++</td><td align="left" colspan="1" rowspan="1">++</td><td align="left" colspan="1" rowspan="1">+</td><td align="left" colspan="1" rowspan="1">++</td><td align="left" colspan="1" rowspan="1">+</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">5 Weeks</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR73">73</xref>, <xref ref-type="bibr" rid="CR75">75</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">db/db&#8201;+&#8201;RAS</td><td align="left" colspan="1" rowspan="1">C57BLKS/J</td><td align="left" colspan="1" rowspan="1">db gene mutation&#8201;+&#8201;surgical renal damage</td><td align="left" colspan="1" rowspan="1">Obesity; Hyperglycemia; Hypertension</td><td align="left" colspan="1" rowspan="1">NR</td><td align="left" colspan="1" rowspan="1">+++</td><td align="left" colspan="1" rowspan="1">+++</td><td align="left" colspan="1" rowspan="1">++</td><td align="left" colspan="1" rowspan="1">++</td><td align="left" colspan="1" rowspan="1">++</td><td align="left" colspan="1" rowspan="1">+</td><td align="left" colspan="1" rowspan="1">+</td><td align="left" colspan="1" rowspan="1">2 Weeks</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR58">58</xref>, <xref ref-type="bibr" rid="CR78">78</xref>]</td></tr></tbody></table><table-wrap-foot><p>Annotation: <bold>Scr</bold>:Serum Creatinine,<bold>UACR</bold>:Urinary Albumin-to-Creatinine Ratio,<bold>Alb</bold>:Albuminuria,<bold>GBM</bold>:glomerular basement membrane,<bold>ME</bold>:Mesangial Expansion,<bold>GS</bold>:Glomerulosclerosis,<bold>IF</bold>:Interstitial fibrosis,<bold>PL</bold>:Podocyte loss,<bold>ObsT</bold>:Observation Time,+: Mild changes, ++: Moderate changes, +++: Severe changes, -: No change; NR: not reported</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec14"><title>Conclusion and future perspectives</title><p id="Par78">Mouse models of diabetic nephropathy (DN) play a pivotal role in elucidating the pathogenesis of DN and in the development of novel therapeutic strategies. This review summarizes various types of DN mouse models, including those induced by chemicals, genetically modified models, and combined approaches. It provides a comprehensive analysis of the characteristics, limitations, and respective advantages and disadvantages of these models in recapitulating the human DN process. Although existing mouse models can mimic certain pathological features observed in human DN&#8212;such as glomerulosclerosis, basement membrane thickening, and mesangial expansion&#8212;the overall complexity and severity of human DN are often not fully reproduced. Therefore, the development of more accurate and comprehensive mouse models of DN remains a pressing challenge in the current research field.</p><p id="Par79">Currently, streptozotocin (STZ) and db/db mice are among the most widely used models for diabetic nephropathy (DN). However, these models are limited to recapitulating the early pathological changes of human DN and fail to fully reproduce the advanced pathological features observed in later stages, which has driven the development of gene-edited models. With the continued advancement of gene editing technologies, more precise and effective animal models can now be generated through techniques such as gene knockout and knock-in. For example, db/db-eNOS&#8211;/&#8211; mice exhibit progressive proteinuria, marked glomerulosclerosis, interstitial fibrosis, and reduced glomerular filtration rate (GFR), thus more closely reflecting the advanced features of clinical diabetic kidney disease (DKD) [<xref ref-type="bibr" rid="CR60">60</xref>]. BTBR ob/ob mice not only develop persistent proteinuria and insulin resistance, but also spontaneously manifest glomerular hypertrophy and severe interstitial fibrosis, making them valuable tools for studying DKD progression [<xref ref-type="bibr" rid="CR67">67</xref>]. OVE26 mice develop severe proteinuria, renal dysfunction, and podocyte loss with age, making them suitable for investigating the pathogenesis of late-stage DKD [<xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR37">37</xref>]. Nevertheless, these models still fall short in recapitulating the typical pathological alterations and severity of human DN, such as classic nodular sclerosis, global glomerulosclerosis, and extensive interstitial fibrosis. In recent years, as the clinical definition of DKD has expanded, increasing attention has been paid to renal injury arising from the combined effects of declining GFR, hypertension, and aging. Incorporating factors such as advanced age and hypertension can further accelerate the progression of kidney injury and enhance the clinical relevance of these models. Such multifactorial models provide more powerful tools for mimicking the complex pathology and heterogeneity of human DKD. In addition, differences among mouse strains can significantly influence model phenotypes, further limiting the reproducibility and translational potential of research findings.</p><p id="Par80">In future research, the development of DKD animal models can be advanced by systematically addressing the limitations of existing models through multi-level and integrated optimization strategies. For instance, the application of multi-gene modification and combined modeling approaches&#8212;such as introducing eNOS gene knockout on a db/db background, or using CRISPR/Cas9 technology to simultaneously knock out multiple genes related to renal injury and inflammation&#8212;can better simulate disease progression under complex genetic conditions. Additionally, combining multiple modeling techniques, such as integrating gene editing with surgical procedures, dietary interventions, and pharmacological induction, may further enhance model fidelity. For example, gene-modified mice can be subjected to high-fat, high-sugar diets, unilateral nephrectomy, aging protocols, hypertension induction, and streptozotocin (STZ) administration to exacerbate renal injury and achieve more severe, clinically relevant DKD phenotypes. This multifactorial approach significantly enriches the phenotypic diversity and clinical relevance of animal models.</p><p id="Par81">Moreover, integrating models of other diabetic complications&#8212;such as diabetic retinopathy and diabetic cardiomyopathy&#8212;can help recapitulate multi-organ systemic damage, better reflecting the complex pathological states observed in clinical patients. On this basis, the incorporation of multi-omics technologies for comprehensive molecular, metabolic, and phenotypic analyses will facilitate a deeper understanding of DKD pathogenesis and the identification of potential therapeutic targets. Through these multidimensional, actively controlled phenotypic enhancement and combined modeling strategies, the scientific value and translational potential of animal models in DKD research and novel therapeutic development can be substantially improved.</p><p id="Par82">In summary, an ideal DKD model should not only exhibit structural injuries such as proteinuria and glomerulosclerosis, but also encompass progressive decline in GFR, hypertension, aging, obesity, and insulin resistance, reflecting a multifactorial and integrated phenotype. In the future, the development of DKD models with greater clinical relevance&#8212;through strategies such as gene editing, multi-omics integration, and combinatorial modeling approaches&#8212;will provide a solid foundation for mechanistic studies and the development of novel therapeutics.</p></sec></body><back><fn-group><fn><p><bold>Publisher&#8217;s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>Not applicable.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>Kang Xie, Yan Ma and Jingjing Din participated in the review of relevant literature.Kang Xie drafted the manuscript and participated in its revision. Yujie Jin, Siwen Zhang, Shiqiang Liu and Cui Yu assisted in drafting the manuscript and organized the figures and tables. Xu Wu and Chunyan Xing contributed to the drafting and revision of the manuscript. Jialin Gao and Lizhuo Wang supervised the study, provided critical revisions, and served as corresponding authors. All authors have read and approved the final manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This work was supported by the Anhui Provincial Health and Medical Research Project-Major Program jointly supported by the Commission and the Province with Provincial Financial Support (2024BAC50001), the National Natural Science Foundation of China (82370808), the &#8220;Climbing Peak&#8221; Training Program for Innovative Technology Team of Yijishan Hospital, Wannan Medical College (PF2019013), the &#8220;Peak&#8221; Training Program for Scientific Research of Yijishan Hospital, Wannan Medical College (GF2019J07), Major Project Funding from the Anhui Provincial Education Department (2023AH040244, 2023AH040245),the Clinical Medical Research Transformation Project of Anhui Province (202204295107020067).</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>No datasets were generated or analysed during the current study.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par83">Not applicable.</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par84">Not applicable.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par85">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="other">Huang H, Luo Y, Wang Q, Zhang Y, Li Z, He R, et al. Vaccinium as potential therapy for diabetes and microvascular complications. Nutrients. 2023;15(9).<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/nu15092031</pub-id><pub-id pub-id-type="pmcid">PMC10181411</pub-id><pub-id pub-id-type="pmid">37432140</pub-id></mixed-citation></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chow</surname><given-names>BSM</given-names></name><name name-style="western"><surname>Allen</surname><given-names>TJ</given-names></name></person-group><article-title>Mouse models for studying diabetic nephropathy</article-title><source>Curr Protoc Mouse Biol</source><year>2015</year><volume>5</volume><issue>2</issue><fpage>85</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">26069079</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/9780470942390.mo140192</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Chow BSM, Allen TJ. Mouse models for studying diabetic nephropathy. Curr Protoc Mouse Biol. 2015;5(2):85&#8211;94.<pub-id pub-id-type="pmid">26069079</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/9780470942390.mo140192</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brosius</surname><given-names>FC</given-names><suffix>III</suffix></name><name name-style="western"><surname>Alpers</surname><given-names>CE</given-names></name><name name-style="western"><surname>Bottinger</surname><given-names>EP</given-names></name><name name-style="western"><surname>Breyer</surname><given-names>MD</given-names></name><name name-style="western"><surname>Coffman</surname><given-names>TM</given-names></name><name name-style="western"><surname>Gurley</surname><given-names>SB</given-names></name><etal/></person-group><article-title>Mouse models of diabetic nephropathy</article-title><source>J Am Soc Nephrol</source><year>2009</year><volume>20</volume><issue>12</issue><fpage>2503</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">19729434</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1681/ASN.2009070721</pub-id><pub-id pub-id-type="pmcid">PMC4075053</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Brosius FC III, Alpers CE, Bottinger EP, Breyer MD, Coffman TM, Gurley SB, et al. Mouse models of diabetic nephropathy. J Am Soc Nephrol. 2009;20(12):2503&#8211;12.<pub-id pub-id-type="pmid">19729434</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1681/ASN.2009070721</pub-id><pub-id pub-id-type="pmcid">PMC4075053</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hanouneh</surname><given-names>M</given-names></name><name name-style="western"><surname>Echouffo Tcheugui</surname><given-names>JB</given-names></name><name name-style="western"><surname>Jaar</surname><given-names>BG</given-names></name></person-group><article-title>Recent advances in diabetic kidney disease</article-title><source>BMC Med</source><year>2021</year><volume>19</volume><fpage>1</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">34399760</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12916-021-02050-0</pub-id><pub-id pub-id-type="pmcid">PMC8369797</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Hanouneh M, Echouffo Tcheugui JB, Jaar BG. Recent advances in diabetic kidney disease. BMC Med. 2021;19:1&#8211;3.<pub-id pub-id-type="pmid">34399760</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12916-021-02050-0</pub-id><pub-id pub-id-type="pmcid">PMC8369797</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Breyer</surname><given-names>MD</given-names></name><name name-style="western"><surname>Bo</surname><given-names>E</given-names></name><name name-style="western"><surname>Brosius</surname><given-names>FC</given-names><suffix>III</suffix></name><name name-style="western"><surname>Coffman</surname><given-names>TM</given-names></name><name name-style="western"><surname>Harris</surname><given-names>RC</given-names></name><name name-style="western"><surname>Heilig</surname><given-names>CW</given-names></name><etal/></person-group><article-title>Mouse models of diabetic nephropathy</article-title><source>J Am Soc Nephrol</source><year>2005</year><volume>16</volume><issue>1</issue><fpage>27</fpage><lpage>45</lpage><pub-id pub-id-type="pmid">15563560</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1681/ASN.2004080648</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Breyer MD, Bo E, Brosius FC III, Coffman TM, Harris RC, Heilig CW, et al. Mouse models of diabetic nephropathy. J Am Soc Nephrol. 2005;16(1):27&#8211;45.<pub-id pub-id-type="pmid">15563560</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1681/ASN.2004080648</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>C</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>C</given-names></name><name name-style="western"><surname>Gao</surname><given-names>Q</given-names></name><name name-style="western"><surname>Bai</surname><given-names>J</given-names></name><name name-style="western"><surname>Si</surname><given-names>J</given-names></name><etal/></person-group><article-title>Ergosterol ameliorates renal inflammatory responses in mice model of diabetic nephropathy</article-title><source>Biomed Pharmacother</source><year>2020</year><volume>128</volume><fpage>110252</fpage><pub-id pub-id-type="pmid">32446112</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biopha.2020.110252</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Liu C, Zhao S, Zhu C, Gao Q, Bai J, Si J, et al. Ergosterol ameliorates renal inflammatory responses in mice model of diabetic nephropathy. Biomed Pharmacother. 2020;128:110252.<pub-id pub-id-type="pmid">32446112</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biopha.2020.110252</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>J</given-names></name><name name-style="western"><surname>Liu</surname><given-names>B</given-names></name><name name-style="western"><surname>Du</surname><given-names>X</given-names></name><name name-style="western"><surname>Wei</surname><given-names>Y</given-names></name><name name-style="western"><surname>Kong</surname><given-names>D</given-names></name><name name-style="western"><surname>Feng</surname><given-names>B</given-names></name><etal/></person-group><article-title>Amelioration of diabetic nephropathy in mice by a single intravenous injection of human mesenchymal stromal cells at early and later disease stages is associated with restoration of autophagy</article-title><source>Stem Cell Res Ther</source><year>2024</year><volume>15</volume><issue>1</issue><fpage>66</fpage><pub-id pub-id-type="pmid">38443965</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13287-024-03647-x</pub-id><pub-id pub-id-type="pmcid">PMC10916232</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">He J, Liu B, Du X, Wei Y, Kong D, Feng B, et al. Amelioration of diabetic nephropathy in mice by a single intravenous injection of human mesenchymal stromal cells at early and later disease stages is associated with restoration of autophagy. Stem Cell Res Ther. 2024;15(1):66.<pub-id pub-id-type="pmid">38443965</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13287-024-03647-x</pub-id><pub-id pub-id-type="pmcid">PMC10916232</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>W</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>H</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H</given-names></name><name name-style="western"><surname>Shen</surname><given-names>J</given-names></name></person-group><article-title>Buyang Huanwu Decoction protects against STZ-induced diabetic nephropathy by inhibiting TGF-&#946;/Smad3 signaling-mediated renal fibrosis and inflammation</article-title><source>Chin Med</source><year>2021</year><volume>16</volume><fpage>1</fpage><lpage>16</lpage><pub-id pub-id-type="pmid">34775979</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13020-021-00531-1</pub-id><pub-id pub-id-type="pmcid">PMC8591830</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Wu W, Wang Y, Li H, Chen H, Shen J. Buyang Huanwu Decoction protects against STZ-induced diabetic nephropathy by inhibiting TGF-&#946;/Smad3 signaling-mediated renal fibrosis and inflammation. Chin Med. 2021;16:1&#8211;16.<pub-id pub-id-type="pmid">34775979</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13020-021-00531-1</pub-id><pub-id pub-id-type="pmcid">PMC8591830</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alpers</surname><given-names>CE</given-names></name><name name-style="western"><surname>Hudkins</surname><given-names>KL</given-names></name></person-group><article-title>Mouse models of diabetic nephropathy</article-title><source>Curr Opin Nephrol Hypertens</source><year>2011</year><volume>20</volume><issue>3</issue><fpage>278</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">21422926</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MNH.0b013e3283451901</pub-id><pub-id pub-id-type="pmcid">PMC3658822</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Alpers CE, Hudkins KL. Mouse models of diabetic nephropathy. Curr Opin Nephrol Hypertens. 2011;20(3):278&#8211;84.<pub-id pub-id-type="pmid">21422926</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MNH.0b013e3283451901</pub-id><pub-id pub-id-type="pmcid">PMC3658822</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><mixed-citation publication-type="other">Zhou X-C, Liang Y-J, Qin L, Wei G-H, Wang J-Q. Astragalus&#8211;saffron&#8211;rhubarb mixture delays the progress of diabetic nephropathy in db/db mice. Diab Metab Synd Obes. 2021:4679-90.<pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/DMSO.S334662</pub-id><pub-id pub-id-type="pmcid">PMC8667760</pub-id><pub-id pub-id-type="pmid">34916815</pub-id></mixed-citation></ref><ref id="CR11"><label>11.</label><mixed-citation publication-type="other">Kitada M, Ogura Y, Koya D. Rodent models of diabetic nephropathy: their utility and limitations. Int J Nephrol Renovascular Disease. 2016:279&#8211;90.<pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/IJNRD.S103784</pub-id><pub-id pub-id-type="pmcid">PMC5115690</pub-id><pub-id pub-id-type="pmid">27881924</pub-id></mixed-citation></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tervaert</surname><given-names>TWC</given-names></name><name name-style="western"><surname>Mooyaart</surname><given-names>AL</given-names></name><name name-style="western"><surname>Amann</surname><given-names>K</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>AH</given-names></name><name name-style="western"><surname>Cook</surname><given-names>HT</given-names></name><name name-style="western"><surname>Drachenberg</surname><given-names>CB</given-names></name><etal/></person-group><article-title>Pathologic classification of diabetic nephropathy</article-title><source>J Am Soc Nephrol</source><year>2010</year><volume>21</volume><issue>4</issue><fpage>556</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">20167701</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1681/ASN.2010010010</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Tervaert TWC, Mooyaart AL, Amann K, Cohen AH, Cook HT, Drachenberg CB, et al. Pathologic classification of diabetic nephropathy. J Am Soc Nephrol. 2010;21(4):556&#8211;63.<pub-id pub-id-type="pmid">20167701</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1681/ASN.2010010010</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tesch</surname><given-names>GH</given-names></name><name name-style="western"><surname>Allen</surname><given-names>TJ</given-names></name></person-group><article-title>Rodent models of streptozotocin-induced diabetic nephropathy (Methods in renal Research)</article-title><source>Nephrology</source><year>2007</year><volume>12</volume><issue>3</issue><fpage>261</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">17498121</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1440-1797.2007.00796.x</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Tesch GH, Allen TJ. Rodent models of streptozotocin-induced diabetic nephropathy (Methods in renal research). Nephrology. 2007;12(3):261&#8211;6.<pub-id pub-id-type="pmid">17498121</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1440-1797.2007.00796.x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Harloff</surname><given-names>M</given-names></name><name name-style="western"><surname>Prueschenk</surname><given-names>S</given-names></name><name name-style="western"><surname>Seifert</surname><given-names>R</given-names></name><name name-style="western"><surname>Schlossmann</surname><given-names>J</given-names></name></person-group><article-title>Activation of soluble Guanylyl cyclase signalling with Cinaciguat improves impaired kidney function in diabetic mice</article-title><source>Br J Pharmacol</source><year>2022</year><volume>179</volume><issue>11</issue><fpage>2460</fpage><lpage>75</lpage><pub-id pub-id-type="pmid">33651375</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/bph.15425</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Harloff M, Prueschenk S, Seifert R, Schlossmann J. Activation of soluble Guanylyl cyclase signalling with Cinaciguat improves impaired kidney function in diabetic mice. Br J Pharmacol. 2022;179(11):2460&#8211;75.<pub-id pub-id-type="pmid">33651375</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/bph.15425</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lenzen</surname><given-names>S</given-names></name></person-group><article-title>The mechanisms of alloxan-and streptozotocin-induced diabetes</article-title><source>Diabetologia</source><year>2008</year><volume>51</volume><issue>2</issue><fpage>216</fpage><lpage>26</lpage><pub-id pub-id-type="pmid">18087688</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00125-007-0886-7</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Lenzen S. The mechanisms of alloxan-and streptozotocin-induced diabetes. Diabetologia. 2008;51(2):216&#8211;26.<pub-id pub-id-type="pmid">18087688</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00125-007-0886-7</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tidke</surname><given-names>PS</given-names></name><name name-style="western"><surname>Patil</surname><given-names>CR</given-names></name></person-group><article-title>Nrf2 activator corosolic acid meliorates Alloxan induced diabetic nephropathy in mice</article-title><source>Asian Pac J Trop Biomed</source><year>2017</year><volume>7</volume><issue>9</issue><fpage>797</fpage><lpage>804</lpage></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Tidke PS, Patil CR. Nrf2 activator corosolic acid meliorates Alloxan induced diabetic nephropathy in mice. Asian Pac J Trop Biomed. 2017;7(9):797&#8211;804.</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><mixed-citation publication-type="other">Yuan Y-L, Guo C-R, Cui L-L, Ruan S-X, Zhang C-F, Ji D, et al. Timosaponin B-II ameliorates diabetic nephropathy via TXNIP, mTOR, and NF-&#954;B signaling pathways in alloxan-induced mice. Dru Des Develop Ther. 2015:6247-58.<pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/DDDT.S96435</pub-id><pub-id pub-id-type="pmcid">PMC4669930</pub-id><pub-id pub-id-type="pmid">26664046</pub-id></mixed-citation></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Radenkovi&#263;</surname><given-names>M</given-names></name><name name-style="western"><surname>Stojanovi&#263;</surname><given-names>M</given-names></name><name name-style="western"><surname>Prostran</surname><given-names>M</given-names></name></person-group><article-title>Experimental diabetes induced by Alloxan and streptozotocin: the current state of the Art</article-title><source>J Pharmacol Toxicol Methods</source><year>2016</year><volume>78</volume><fpage>13</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">26596652</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vascn.2015.11.004</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Radenkovi&#263; M, Stojanovi&#263; M, Prostran M. Experimental diabetes induced by alloxan and streptozotocin: the current state of the art. J Pharmacol Toxicol Methods. 2016;78:13&#8211;31.<pub-id pub-id-type="pmid">26596652</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vascn.2015.11.004</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maeda</surname><given-names>M</given-names></name><name name-style="western"><surname>Yabuki</surname><given-names>A</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>S</given-names></name><name name-style="western"><surname>Matsumoto</surname><given-names>M</given-names></name><name name-style="western"><surname>Taniguchi</surname><given-names>K</given-names></name><name name-style="western"><surname>Nishinakagawa</surname><given-names>H</given-names></name></person-group><article-title>Renal lesions in spontaneous insulin-dependent diabetes mellitus in the Nonobese diabetic mouse: acute phase of diabetes</article-title><source>Vet Pathol</source><year>2003</year><volume>40</volume><issue>2</issue><fpage>187</fpage><lpage>95</lpage><pub-id pub-id-type="pmid">12637759</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1354/vp.40-2-187</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Maeda M, Yabuki A, Suzuki S, Matsumoto M, Taniguchi K, Nishinakagawa H. Renal lesions in spontaneous insulin-dependent diabetes mellitus in the nonobese diabetic mouse: acute phase of diabetes. Vet Pathol. 2003;40(2):187&#8211;95.<pub-id pub-id-type="pmid">12637759</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1354/vp.40-2-187</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kolb</surname><given-names>H</given-names></name></person-group><article-title>Mouse models of insulin dependent diabetes: Low-dose streptozocin&#8208;induced diabetes and Nonobese diabetic (NOD) mice</article-title><source>Diabetes Metab Res Rev</source><year>1987</year><volume>3</volume><issue>3</issue><fpage>751</fpage><lpage>78</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/dmr.5610030308</pub-id><pub-id pub-id-type="pmid">2956075</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Kolb H. Mouse models of insulin dependent diabetes: Low-dose streptozocin&#8208;induced diabetes and Nonobese diabetic (NOD) mice. Diabetes Metab Res Rev. 1987;3(3):751&#8211;78.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/dmr.5610030308</pub-id><pub-id pub-id-type="pmid">2956075</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Makino</surname><given-names>S</given-names></name><name name-style="western"><surname>Kunimoto</surname><given-names>K</given-names></name><name name-style="western"><surname>Muraoka</surname><given-names>Y</given-names></name><name name-style="western"><surname>Mizushima</surname><given-names>Y</given-names></name><name name-style="western"><surname>KATAGIRI</surname><given-names>K</given-names></name><name name-style="western"><surname>TOCHINO</surname><given-names>Y</given-names></name></person-group><article-title>Breeding of a non-obese, diabetic strain of mice</article-title><source>Exp Anim</source><year>1980</year><volume>29</volume><issue>1</issue><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1538/expanim1978.29.1_1</pub-id><pub-id pub-id-type="pmid">6995140</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Makino S, Kunimoto K, Muraoka Y, Mizushima Y, Katagiri K, Tochino Y. Breeding of a non-obese, diabetic strain of mice. Exp Anim. 1980;29(1):1&#8211;13.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1538/expanim1978.29.1_1</pub-id><pub-id pub-id-type="pmid">6995140</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leiter</surname><given-names>EH</given-names></name><name name-style="western"><surname>Prochazka</surname><given-names>M</given-names></name><name name-style="western"><surname>Coleman</surname><given-names>DL</given-names></name></person-group><article-title>The non-obese diabetic (NOD) mouse</article-title><source>Am J Pathol</source><year>1987</year><volume>128</volume><issue>2</issue><fpage>380</fpage><pub-id pub-id-type="pmid">3303953</pub-id><pub-id pub-id-type="pmcid">PMC1899627</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Leiter EH, Prochazka M, Coleman DL. The non-obese diabetic (NOD) mouse. Am J Pathol. 1987;128(2):380.<pub-id pub-id-type="pmid">3303953</pub-id><pub-id pub-id-type="pmcid">PMC1899627</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><mixed-citation publication-type="other">Driver JP, Serreze DV, Chen Y-G, editors. Mouse models for the study of autoimmune type 1 diabetes: a NOD to similarities and differences to human disease. Seminars in immunopathology. Springer; 2011.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00281-010-0204-1</pub-id><pub-id pub-id-type="pmid">20424843</pub-id></mixed-citation></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O&#8217;Kell</surname><given-names>AL</given-names></name><name name-style="western"><surname>Wasserfall</surname><given-names>C</given-names></name><name name-style="western"><surname>Catchpole</surname><given-names>B</given-names></name><name name-style="western"><surname>Davison</surname><given-names>LJ</given-names></name><name name-style="western"><surname>Hess</surname><given-names>RS</given-names></name><name name-style="western"><surname>Kushner</surname><given-names>JA</given-names></name><etal/></person-group><article-title>Comparative pathogenesis of autoimmune diabetes in humans, NOD mice, and canines: has a valuable animal model of type 1 diabetes been overlooked?</article-title><source>Diabetes</source><year>2017</year><volume>66</volume><issue>6</issue><fpage>1443</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">28533295</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/db16-1551</pub-id><pub-id pub-id-type="pmcid">PMC5440022</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">O&#8217;Kell AL, Wasserfall C, Catchpole B, Davison LJ, Hess RS, Kushner JA, et al. Comparative pathogenesis of autoimmune diabetes in humans, NOD mice, and canines: has a valuable animal model of type 1 diabetes been overlooked? Diabetes. 2017;66(6):1443&#8211;52.<pub-id pub-id-type="pmid">28533295</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/db16-1551</pub-id><pub-id pub-id-type="pmcid">PMC5440022</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><mixed-citation publication-type="other">Kimura S, Hirasawa T, Nakamura K, Yagi H, Matsumoto M, Makino S et al. Genetic control of peripheral T-cell deficiency in the cataract Shionogi (CTS) mouse linked to chromosome 7. 1998.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s002510050358</pub-id><pub-id pub-id-type="pmid">9435347</pub-id></mixed-citation></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Delovitch</surname><given-names>TL</given-names></name><name name-style="western"><surname>Singh</surname><given-names>B</given-names></name></person-group><article-title>The Nonobese diabetic mouse as a model of autoimmune diabetes: immune dysregulation gets the NOD</article-title><source>Immunity</source><year>1997</year><volume>7</volume><issue>6</issue><fpage>727</fpage><lpage>38</lpage><pub-id pub-id-type="pmid">9430219</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s1074-7613(00)80392-1</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Delovitch TL, Singh B. The nonobese diabetic mouse as a model of autoimmune diabetes: immune dysregulation gets the NOD. Immunity. 1997;7(6):727&#8211;38.<pub-id pub-id-type="pmid">9430219</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s1074-7613(00)80392-1</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aubin</surname><given-names>A-M</given-names></name><name name-style="western"><surname>Lombard-Vadnais</surname><given-names>F</given-names></name><name name-style="western"><surname>Collin</surname><given-names>R</given-names></name><name name-style="western"><surname>Aliesky</surname><given-names>HA</given-names></name><name name-style="western"><surname>McLachlan</surname><given-names>SM</given-names></name><name name-style="western"><surname>Lesage</surname><given-names>S</given-names></name></person-group><article-title>The NOD mouse beyond autoimmune diabetes</article-title><source>Front Immunol</source><year>2022</year><volume>13</volume><fpage>874769</fpage><pub-id pub-id-type="pmid">35572553</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2022.874769</pub-id><pub-id pub-id-type="pmcid">PMC9102607</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Aubin A-M, Lombard-Vadnais F, Collin R, Aliesky HA, McLachlan SM, Lesage S. The NOD mouse beyond autoimmune diabetes. Front Immunol. 2022;13:874769.<pub-id pub-id-type="pmid">35572553</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2022.874769</pub-id><pub-id pub-id-type="pmcid">PMC9102607</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zheng</surname><given-names>F</given-names></name><name name-style="western"><surname>He</surname><given-names>C</given-names></name><name name-style="western"><surname>Cai</surname><given-names>W</given-names></name><name name-style="western"><surname>Hattori</surname><given-names>M</given-names></name><name name-style="western"><surname>Steffes</surname><given-names>M</given-names></name><name name-style="western"><surname>Vlassara</surname><given-names>H</given-names></name></person-group><article-title>Prevention of diabetic nephropathy in mice by a diet low in glycoxidation products</article-title><source>Diab/Metab Res Rev</source><year>2002</year><volume>18</volume><issue>3</issue><fpage>224</fpage><lpage>37</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/dmrr.283</pub-id><pub-id pub-id-type="pmid">12112941</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Zheng F, He C, Cai W, Hattori M, Steffes M, Vlassara H. Prevention of diabetic nephropathy in mice by a diet low in glycoxidation products. Diab/Metab Res Rev. 2002;18(3):224&#8211;37.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/dmrr.283</pub-id><pub-id pub-id-type="pmid">12112941</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yoshioka</surname><given-names>M</given-names></name><name name-style="western"><surname>Kayo</surname><given-names>T</given-names></name><name name-style="western"><surname>Ikeda</surname><given-names>T</given-names></name><name name-style="western"><surname>Koizuni</surname><given-names>A</given-names></name></person-group><article-title>A novel locus, Mody4, distal to D7Mit189 on chromosome 7 determines early-onset NIDDM in Nonobese C57BL/6 (Akita) mutant mice</article-title><source>Diabetes</source><year>1997</year><volume>46</volume><issue>5</issue><fpage>887</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">9133560</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/diab.46.5.887</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Yoshioka M, Kayo T, Ikeda T, Koizuni A. A novel locus, Mody4, distal to D7Mit189 on chromosome 7 determines early-onset NIDDM in Nonobese C57BL/6 (Akita) mutant mice. Diabetes. 1997;46(5):887&#8211;94.<pub-id pub-id-type="pmid">9133560</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/diab.46.5.887</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Takeuchi</surname><given-names>T</given-names></name><name name-style="western"><surname>Tanaka</surname><given-names>S</given-names></name><name name-style="western"><surname>Kubo</surname><given-names>S-K</given-names></name><name name-style="western"><surname>Kayo</surname><given-names>T</given-names></name><name name-style="western"><surname>Lu</surname><given-names>D</given-names></name><etal/></person-group><article-title>A mutation in the insulin 2 gene induces diabetes with severe pancreatic &#946;-cell dysfunction in the Mody mouse</article-title><source>J Clin Investig</source><year>1999</year><volume>103</volume><issue>1</issue><fpage>27</fpage><lpage>37</lpage><pub-id pub-id-type="pmid">9884331</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/JCI4431</pub-id><pub-id pub-id-type="pmcid">PMC407861</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Wang J, Takeuchi T, Tanaka S, Kubo S-K, Kayo T, Lu D, et al. A mutation in the insulin 2 gene induces diabetes with severe pancreatic &#946;-cell dysfunction in the mody mouse. J Clin Investig. 1999;103(1):27&#8211;37.<pub-id pub-id-type="pmid">9884331</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/JCI4431</pub-id><pub-id pub-id-type="pmcid">PMC407861</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>King</surname><given-names>AJ</given-names></name></person-group><article-title>The use of animal models in diabetes research</article-title><source>Br J Pharmacol</source><year>2012</year><volume>166</volume><issue>3</issue><fpage>877</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">22352879</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1476-5381.2012.01911.x</pub-id><pub-id pub-id-type="pmcid">PMC3417415</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">King AJ. The use of animal models in diabetes research. Br J Pharmacol. 2012;166(3):877&#8211;94.<pub-id pub-id-type="pmid">22352879</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1476-5381.2012.01911.x</pub-id><pub-id pub-id-type="pmcid">PMC3417415</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haseyama</surname><given-names>T</given-names></name><name name-style="western"><surname>Fujita</surname><given-names>T</given-names></name><name name-style="western"><surname>Hirasawa</surname><given-names>F</given-names></name><name name-style="western"><surname>Tsukada</surname><given-names>M</given-names></name><name name-style="western"><surname>Wakui</surname><given-names>H</given-names></name><name name-style="western"><surname>Komatsuda</surname><given-names>A</given-names></name><etal/></person-group><article-title>Complications of IgA nephropathy in a non-insulin-dependent diabetes model, the Akita mouse</article-title><source>Tohoku J Exp Med</source><year>2002</year><volume>198</volume><issue>4</issue><fpage>233</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">12630555</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1620/tjem.198.233</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Haseyama T, Fujita T, Hirasawa F, Tsukada M, Wakui H, Komatsuda A, et al. Complications of IgA nephropathy in a non-insulin-dependent diabetes model, the Akita mouse. Tohoku J Exp Med. 2002;198(4):233&#8211;44.<pub-id pub-id-type="pmid">12630555</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1620/tjem.198.233</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kanauchi</surname><given-names>M</given-names></name><name name-style="western"><surname>Kawano</surname><given-names>T</given-names></name><name name-style="western"><surname>Dohi</surname><given-names>K</given-names></name></person-group><article-title>Serum IgA levels in patients with diabetic nephropathy and IgA nephropathy superimposed on diabetes mellitus</article-title><source>Diabetes Res Clin Pract</source><year>2000</year><volume>48</volume><issue>2</issue><fpage>113</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">10802148</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0168-8227(99)00146-1</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Kanauchi M, Kawano T, Dohi K. Serum IgA levels in patients with diabetic nephropathy and IgA nephropathy superimposed on diabetes mellitus. Diabetes Res Clin Pract. 2000;48(2):113&#8211;8.<pub-id pub-id-type="pmid">10802148</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0168-8227(99)00146-1</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Uruno</surname><given-names>A</given-names></name><name name-style="western"><surname>Saito</surname><given-names>R</given-names></name><name name-style="western"><surname>Matsukawa</surname><given-names>N</given-names></name><name name-style="western"><surname>Hishinuma</surname><given-names>E</given-names></name><name name-style="western"><surname>Saigusa</surname><given-names>D</given-names></name><etal/></person-group><article-title>Nrf2 deficiency deteriorates diabetic kidney disease in Akita model mice</article-title><source>Redox Biol</source><year>2022</year><volume>58</volume><fpage>102525</fpage><pub-id pub-id-type="pmid">36335764</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.redox.2022.102525</pub-id><pub-id pub-id-type="pmcid">PMC9641024</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Liu Y, Uruno A, Saito R, Matsukawa N, Hishinuma E, Saigusa D, et al. Nrf2 deficiency deteriorates diabetic kidney disease in Akita model mice. Redox Biol. 2022;58:102525.<pub-id pub-id-type="pmid">36335764</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.redox.2022.102525</pub-id><pub-id pub-id-type="pmcid">PMC9641024</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Epstein</surname><given-names>PN</given-names></name><name name-style="western"><surname>Overbeek</surname><given-names>PA</given-names></name><name name-style="western"><surname>Means</surname><given-names>AR</given-names></name></person-group><article-title>Calmodulin-induced early-onset diabetes in Transgenic mice</article-title><source>Cell</source><year>1989</year><volume>58</volume><issue>6</issue><fpage>1067</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">2673540</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0092-8674(89)90505-9</pub-id></element-citation><mixed-citation id="mc-CR35" publication-type="journal">Epstein PN, Overbeek PA, Means AR. Calmodulin-induced early-onset diabetes in Transgenic mice. Cell. 1989;58(6):1067&#8211;73.<pub-id pub-id-type="pmid">2673540</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0092-8674(89)90505-9</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zheng</surname><given-names>S</given-names></name><name name-style="western"><surname>Noonan</surname><given-names>WT</given-names></name><name name-style="western"><surname>Metreveli</surname><given-names>NS</given-names></name><name name-style="western"><surname>Coventry</surname><given-names>S</given-names></name><name name-style="western"><surname>Kralik</surname><given-names>PM</given-names></name><name name-style="western"><surname>Carlson</surname><given-names>EC</given-names></name><etal/></person-group><article-title>Development of late-stage diabetic nephropathy in OVE26 diabetic mice</article-title><source>Diabetes</source><year>2004</year><volume>53</volume><issue>12</issue><fpage>3248</fpage><lpage>57</lpage><pub-id pub-id-type="pmid">15561957</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/diabetes.53.12.3248</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">Zheng S, Noonan WT, Metreveli NS, Coventry S, Kralik PM, Carlson EC, et al. Development of late-stage diabetic nephropathy in OVE26 diabetic mice. Diabetes. 2004;53(12):3248&#8211;57.<pub-id pub-id-type="pmid">15561957</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/diabetes.53.12.3248</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Teiken</surname><given-names>JM</given-names></name><name name-style="western"><surname>Audettey</surname><given-names>JL</given-names></name><name name-style="western"><surname>Laturnus</surname><given-names>DI</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>S</given-names></name><name name-style="western"><surname>Epstein</surname><given-names>PN</given-names></name><name name-style="western"><surname>Carlson</surname><given-names>EC</given-names></name></person-group><article-title>Podocyte loss in aging OVE26 diabetic mice</article-title><source>Anat Record: Adv Integr Anat Evolutionary Biology</source><year>2008</year><volume>291</volume><issue>1</issue><fpage>114</fpage><lpage>21</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ar.20625</pub-id><pub-id pub-id-type="pmid">18085629</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">Teiken JM, Audettey JL, Laturnus DI, Zheng S, Epstein PN, Carlson EC. Podocyte loss in aging OVE26 diabetic mice. Anat Record: Adv Integr Anat Evolutionary Biology. 2008;291(1):114&#8211;21.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ar.20625</pub-id><pub-id pub-id-type="pmid">18085629</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>W</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>S</given-names></name><name name-style="western"><surname>Tang</surname><given-names>X</given-names></name><name name-style="western"><surname>Cai</surname><given-names>L</given-names></name><name name-style="western"><surname>Epstein</surname><given-names>P</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Sex differences in progression of diabetic nephropathy in OVE26 type 1 diabetic mice</article-title><source>Biochim Et Biophys Acta (BBA)-Molecular Basis Disease</source><year>2020</year><volume>1866</volume><issue>1</issue><fpage>165589</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbadis.2019.165589</pub-id><pub-id pub-id-type="pmid">31678163</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Wang W, Jiang S, Tang X, Cai L, Epstein P, Cheng Y, et al. Sex differences in progression of diabetic nephropathy in OVE26 type 1 diabetic mice. Biochim Et Biophys Acta (BBA)-Molecular Basis Disease. 2020;1866(1):165589.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbadis.2019.165589</pub-id><pub-id pub-id-type="pmid">31678163</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nakagawa</surname><given-names>T</given-names></name><name name-style="western"><surname>Sato</surname><given-names>W</given-names></name><name name-style="western"><surname>Glushakova</surname><given-names>O</given-names></name><name name-style="western"><surname>Heinig</surname><given-names>M</given-names></name><name name-style="western"><surname>Clarke</surname><given-names>T</given-names></name><name name-style="western"><surname>Campbell-Thompson</surname><given-names>M</given-names></name><etal/></person-group><article-title>Diabetic endothelial nitric oxide synthase knockout mice develop advanced diabetic nephropathy</article-title><source>J Am Soc Nephrol</source><year>2007</year><volume>18</volume><issue>2</issue><fpage>539</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">17202420</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1681/ASN.2006050459</pub-id></element-citation><mixed-citation id="mc-CR39" publication-type="journal">Nakagawa T, Sato W, Glushakova O, Heinig M, Clarke T, Campbell-Thompson M, et al. Diabetic endothelial nitric oxide synthase knockout mice develop advanced diabetic nephropathy. J Am Soc Nephrol. 2007;18(2):539&#8211;50.<pub-id pub-id-type="pmid">17202420</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1681/ASN.2006050459</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>F</given-names></name><name name-style="western"><surname>WANG</surname><given-names>CH</given-names></name><name name-style="western"><surname>WANG</surname><given-names>JG</given-names></name><name name-style="western"><surname>Thai</surname><given-names>T</given-names></name><name name-style="western"><surname>Boysen</surname><given-names>G</given-names></name><name name-style="western"><surname>Xu</surname><given-names>L</given-names></name><etal/></person-group><article-title>Elevated tissue factor expression contributes to exacerbated diabetic nephropathy in mice lacking eNOS fed a high fat diet</article-title><source>J Thromb Haemost</source><year>2010</year><volume>8</volume><issue>10</issue><fpage>2122</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">20626618</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1538-7836.2010.03976.x</pub-id><pub-id pub-id-type="pmcid">PMC5744483</pub-id></element-citation><mixed-citation id="mc-CR40" publication-type="journal">Li F, Wang CH, Wang JG, Thai T, Boysen G, Xu L, et al. Elevated tissue factor expression contributes to exacerbated diabetic nephropathy in mice lacking eNOS fed a high fat diet. J Thromb Haemost. 2010;8(10):2122&#8211;32.<pub-id pub-id-type="pmid">20626618</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1538-7836.2010.03976.x</pub-id><pub-id pub-id-type="pmcid">PMC5744483</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Takahashi</surname><given-names>T</given-names></name><name name-style="western"><surname>Harris</surname><given-names>RC</given-names></name></person-group><article-title>Role of endothelial nitric oxide synthase in diabetic nephropathy: lessons from diabetic eNOS knockout mice</article-title><source>J Diabetes Res</source><year>2014</year><volume>2014</volume><issue>1</issue><fpage>590541</fpage><pub-id pub-id-type="pmid">25371905</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2014/590541</pub-id><pub-id pub-id-type="pmcid">PMC4211249</pub-id></element-citation><mixed-citation id="mc-CR41" publication-type="journal">Takahashi T, Harris RC. Role of endothelial nitric oxide synthase in diabetic nephropathy: lessons from diabetic eNOS knockout mice. J Diabetes Res. 2014;2014(1):590541.<pub-id pub-id-type="pmid">25371905</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2014/590541</pub-id><pub-id pub-id-type="pmcid">PMC4211249</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Steffes</surname><given-names>MW</given-names></name><name name-style="western"><surname>Brown</surname><given-names>DM</given-names></name><name name-style="western"><surname>Michael Mauer</surname><given-names>S</given-names></name></person-group><article-title>Diabetic glomerulopathy following unilateral nephrectomy in the rat</article-title><source>Diabetes</source><year>1978</year><volume>27</volume><issue>1</issue><fpage>35</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">340310</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/diab.27.1.35</pub-id></element-citation><mixed-citation id="mc-CR42" publication-type="journal">Steffes MW, Brown DM, Michael Mauer S. Diabetic glomerulopathy following unilateral nephrectomy in the rat. Diabetes. 1978;27(1):35&#8211;41.<pub-id pub-id-type="pmid">340310</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/diab.27.1.35</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wada</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name><name name-style="western"><surname>Tsuchiyama</surname><given-names>Y</given-names></name><name name-style="western"><surname>Hiragushi</surname><given-names>K</given-names></name><name name-style="western"><surname>Hida</surname><given-names>K</given-names></name><name name-style="western"><surname>Shikata</surname><given-names>K</given-names></name><etal/></person-group><article-title>Gene expression profile in streptozotocin-induced diabetic mice kidneys undergoing glomerulosclerosis</article-title><source>Kidney Int</source><year>2001</year><volume>59</volume><issue>4</issue><fpage>1363</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">11260397</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1046/j.1523-1755.2001.0590041363.x</pub-id></element-citation><mixed-citation id="mc-CR43" publication-type="journal">Wada J, Zhang H, Tsuchiyama Y, Hiragushi K, Hida K, Shikata K, et al. Gene expression profile in streptozotocin-induced diabetic mice kidneys undergoing glomerulosclerosis. Kidney Int. 2001;59(4):1363&#8211;73.<pub-id pub-id-type="pmid">11260397</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1046/j.1523-1755.2001.0590041363.x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Uil</surname><given-names>M</given-names></name><name name-style="western"><surname>Scantlebery</surname><given-names>AM</given-names></name><name name-style="western"><surname>Butter</surname><given-names>LM</given-names></name><name name-style="western"><surname>Larsen</surname><given-names>PW</given-names></name><name name-style="western"><surname>de Boer</surname><given-names>OJ</given-names></name><name name-style="western"><surname>Leemans</surname><given-names>JC</given-names></name><etal/></person-group><article-title>Combining streptozotocin and unilateral nephrectomy is an effective method for inducing experimental diabetic nephropathy in the &#8216;resistant&#8217;C57Bl/6J mouse strain</article-title><source>Sci Rep</source><year>2018</year><volume>8</volume><issue>1</issue><fpage>5542</fpage><pub-id pub-id-type="pmid">29615804</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-018-23839-9</pub-id><pub-id pub-id-type="pmcid">PMC5882654</pub-id></element-citation><mixed-citation id="mc-CR44" publication-type="journal">Uil M, Scantlebery AM, Butter LM, Larsen PW, de Boer OJ, Leemans JC, et al. Combining streptozotocin and unilateral nephrectomy is an effective method for inducing experimental diabetic nephropathy in the &#8216;resistant&#8217;C57Bl/6J mouse strain. Sci Rep. 2018;8(1):5542.<pub-id pub-id-type="pmid">29615804</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-018-23839-9</pub-id><pub-id pub-id-type="pmcid">PMC5882654</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lim</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Yang</surname><given-names>H-C</given-names></name><name name-style="western"><surname>Fogo</surname><given-names>AB</given-names></name></person-group><article-title>Animal models of regression/progression of kidney disease</article-title><source>Drug Discovery Today: Disease Models</source><year>2014</year><volume>11</volume><fpage>45</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">25722733</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ddmod.2014.06.003</pub-id><pub-id pub-id-type="pmcid">PMC4337226</pub-id></element-citation><mixed-citation id="mc-CR45" publication-type="journal">Lim BJ, Yang H-C, Fogo AB. Animal models of regression/progression of kidney disease. Drug Discovery Today: Disease Models. 2014;11:45&#8211;51.<pub-id pub-id-type="pmid">25722733</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ddmod.2014.06.003</pub-id><pub-id pub-id-type="pmcid">PMC4337226</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chiang</surname><given-names>K-H</given-names></name><name name-style="western"><surname>Chiu</surname><given-names>Y-C</given-names></name><name name-style="western"><surname>Yar</surname><given-names>N</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y-C</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>C-H</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y-C</given-names></name><etal/></person-group><article-title>Renoprotective impacts of inonotus obliquus ethanol-ethyl acetate extract on combined streptozotocin and unilateral nephrectomy-induced diabetic nephropathy in mice</article-title><source>Int J Mol Sci</source><year>2023</year><volume>24</volume><issue>5</issue><fpage>4443</fpage><pub-id pub-id-type="pmid">36901874</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms24054443</pub-id><pub-id pub-id-type="pmcid">PMC10002342</pub-id></element-citation><mixed-citation id="mc-CR46" publication-type="journal">Chiang K-H, Chiu Y-C, Yar N, Chen Y-C, Cheng C-H, Liu Y-C, et al. Renoprotective impacts of inonotus obliquus ethanol-ethyl acetate extract on combined streptozotocin and unilateral nephrectomy-induced diabetic nephropathy in mice. Int J Mol Sci. 2023;24(5):4443.<pub-id pub-id-type="pmid">36901874</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms24054443</pub-id><pub-id pub-id-type="pmcid">PMC10002342</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><mixed-citation publication-type="other">Wang C-Y, Liao JK. A mouse model of diet-induced obesity and insulin resistance. Mtor: Methods and Protocols. 2012:421&#8211;33.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/978-1-61779-430-8_27</pub-id><pub-id pub-id-type="pmcid">PMC3807094</pub-id><pub-id pub-id-type="pmid">22125082</pub-id></mixed-citation></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>G</given-names></name><name name-style="western"><surname>Cui</surname><given-names>J</given-names></name><name name-style="western"><surname>Xie</surname><given-names>S</given-names></name><name name-style="western"><surname>Wan</surname><given-names>H</given-names></name><name name-style="western"><surname>Luo</surname><given-names>Y</given-names></name><name name-style="western"><surname>Guo</surname><given-names>G</given-names></name><name name-style="western"><surname>Bioscience</surname></name></person-group><source>Biotechnol Biochem</source><year>2021</year><volume>85</volume><issue>5</issue><fpage>1183</fpage><lpage>93</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bbb/zbab012</pub-id><pub-id pub-id-type="pmid">33704405</pub-id></element-citation><mixed-citation id="mc-CR48" publication-type="journal">Zhou G, Cui J, Xie S, Wan H, Luo Y, Guo G, Bioscience. Biotechnol Biochem. 2021;85(5):1183&#8211;93.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bbb/zbab012</pub-id><pub-id pub-id-type="pmid">33704405</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sangartit</surname><given-names>W</given-names></name><name name-style="western"><surname>Ha</surname><given-names>KB</given-names></name><name name-style="western"><surname>Lee</surname><given-names>ES</given-names></name><name name-style="western"><surname>Kim</surname><given-names>HM</given-names></name><name name-style="western"><surname>Kukongviriyapan</surname><given-names>U</given-names></name><name name-style="western"><surname>Lee</surname><given-names>EY</given-names></name><etal/></person-group><article-title>Tetrahydrocurcumin ameliorates kidney injury and high systolic blood pressure in high-fat diet-induced type 2 diabetic mice</article-title><source>Endocrinol Metabolism</source><year>2021</year><volume>36</volume><issue>4</issue><fpage>810</fpage><lpage>22</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.3803/EnM.2021.988</pub-id><pub-id pub-id-type="pmcid">PMC8419617</pub-id><pub-id pub-id-type="pmid">34474516</pub-id></element-citation><mixed-citation id="mc-CR49" publication-type="journal">Sangartit W, Ha KB, Lee ES, Kim HM, Kukongviriyapan U, Lee EY, et al. Tetrahydrocurcumin ameliorates kidney injury and high systolic blood pressure in high-fat diet-induced type 2 diabetic mice. Endocrinol Metabolism. 2021;36(4):810&#8211;22.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3803/EnM.2021.988</pub-id><pub-id pub-id-type="pmcid">PMC8419617</pub-id><pub-id pub-id-type="pmid">34474516</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>da Silva Xavier</surname><given-names>G</given-names></name><name name-style="western"><surname>Hodson</surname><given-names>DJ</given-names></name></person-group><article-title>Mouse models of peripheral metabolic disease</article-title><source>Best Pract Res Clin Endocrinol Metab</source><year>2018</year><volume>32</volume><issue>3</issue><fpage>299</fpage><lpage>315</lpage><pub-id pub-id-type="pmid">29779583</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.beem.2018.03.009</pub-id></element-citation><mixed-citation id="mc-CR50" publication-type="journal">da Silva Xavier G, Hodson DJ. Mouse models of peripheral metabolic disease. Best Pract Res Clin Endocrinol Metab. 2018;32(3):299&#8211;315.<pub-id pub-id-type="pmid">29779583</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.beem.2018.03.009</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bielschowsky</surname><given-names>M</given-names></name><name name-style="western"><surname>Goodall</surname><given-names>C</given-names></name></person-group><article-title>Origin of inbred NZ mouse strains</article-title><source>Cancer Res</source><year>1970</year><volume>30</volume><issue>3</issue><fpage>834</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">5425297</pub-id></element-citation><mixed-citation id="mc-CR51" publication-type="journal">Bielschowsky M, Goodall C. Origin of inbred NZ mouse strains. Cancer Res. 1970;30(3):834&#8211;6.<pub-id pub-id-type="pmid">5425297</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><mixed-citation publication-type="other">Bielschowsky M, Bielschowsky F. The New Zealand strain of obese mice their response to stilboestrol and to insulin. Australian J Experimental Biology Med Sci. 1956;34(3).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/icb.1956.22</pub-id><pub-id pub-id-type="pmid">13363746</pub-id></mixed-citation></ref><ref id="CR53"><label>53.</label><mixed-citation publication-type="other">Kluge R, Scherneck S, Sch&#252;rmann A, Joost H-G. Pathophysiology and genetics of obesity and diabetes in the New Zealand obese mouse: a model of the human metabolic syndrome. Anim Models Diabetes Res. 2012:59&#8211;73.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/978-1-62703-068-7_5</pub-id><pub-id pub-id-type="pmid">22893401</pub-id></mixed-citation></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ortlepp</surname><given-names>K</given-names></name><name name-style="western"><surname>Giesen, Plum, Radke</surname><given-names>H</given-names></name><etal/></person-group><article-title>A metabolic syndrome of hypertension, hyperinsulinaemia and hypercholesterolaemia in the new Zealand obese mouse</article-title><source>Eur J Clin Invest</source><year>2000</year><volume>30</volume><issue>3</issue><fpage>195</fpage><lpage>202</lpage><pub-id pub-id-type="pmid">10691995</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1046/j.1365-2362.2000.00611.x</pub-id></element-citation><mixed-citation id="mc-CR54" publication-type="journal">Ortlepp K, Giesen, Plum, Radke H, et al. A metabolic syndrome of hypertension, hyperinsulinaemia and hypercholesterolaemia in the New Zealand obese mouse. Eur J Clin Invest. 2000;30(3):195&#8211;202.<pub-id pub-id-type="pmid">10691995</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1046/j.1365-2362.2000.00611.x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Melez</surname><given-names>KA</given-names></name><name name-style="western"><surname>Harrison</surname><given-names>LC</given-names></name><name name-style="western"><surname>Gilliam</surname><given-names>JN</given-names></name><name name-style="western"><surname>Steinberg</surname><given-names>AD</given-names></name></person-group><article-title>Diabetes is associated with autoimmunity in the new Zealand obese (NZO) mouse</article-title><source>Diabetes</source><year>1980</year><volume>29</volume><issue>10</issue><fpage>835</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">7002665</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/diacare.20.10.835</pub-id></element-citation><mixed-citation id="mc-CR55" publication-type="journal">Melez KA, Harrison LC, Gilliam JN, Steinberg AD. Diabetes is associated with autoimmunity in the New Zealand obese (NZO) mouse. Diabetes. 1980;29(10):835&#8211;40.<pub-id pub-id-type="pmid">7002665</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/diacare.20.10.835</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR56"><label>56.</label><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zheng</surname><given-names>Z</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Kr&#252;gel</surname><given-names>U</given-names></name><name name-style="western"><surname>Schaefer</surname><given-names>M</given-names></name><name name-style="western"><surname>Grune</surname><given-names>T</given-names></name><name name-style="western"><surname>N&#252;rnberg</surname><given-names>B</given-names></name><etal/></person-group><article-title>In vivo Inhibition of TRPC6 by SH045 attenuates renal fibrosis in a new Zealand obese (NZO) mouse model of metabolic syndrome</article-title><source>Int J Mol Sci</source><year>2022</year><volume>23</volume><issue>12</issue><fpage>6870</fpage><pub-id pub-id-type="pmid">35743312</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms23126870</pub-id><pub-id pub-id-type="pmcid">PMC9224794</pub-id></element-citation><mixed-citation id="mc-CR56" publication-type="journal">Zheng Z, Xu Y, Kr&#252;gel U, Schaefer M, Grune T, N&#252;rnberg B, et al. In vivo Inhibition of TRPC6 by SH045 attenuates renal fibrosis in a New Zealand obese (NZO) mouse model of metabolic syndrome. Int J Mol Sci. 2022;23(12):6870.<pub-id pub-id-type="pmid">35743312</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms23126870</pub-id><pub-id pub-id-type="pmcid">PMC9224794</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR57"><label>57.</label><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hummel</surname><given-names>KP</given-names></name><name name-style="western"><surname>Dickie</surname><given-names>MM</given-names></name><name name-style="western"><surname>Coleman</surname><given-names>DL</given-names></name></person-group><article-title>Diabetes, a new mutation in the mouse</article-title><source>Science</source><year>1966</year><volume>153</volume><issue>3740</issue><fpage>1127</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">5918576</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.153.3740.1127</pub-id></element-citation><mixed-citation id="mc-CR57" publication-type="journal">Hummel KP, Dickie MM, Coleman DL. Diabetes, a new mutation in the mouse. Science. 1966;153(3740):1127&#8211;8.<pub-id pub-id-type="pmid">5918576</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.153.3740.1127</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR58"><label>58.</label><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tesch</surname><given-names>GH</given-names></name><name name-style="western"><surname>Lim</surname><given-names>AK-H</given-names></name></person-group><article-title>Recent insights into diabetic renal injury from the db/db mouse model of type 2 diabetic nephropathy</article-title><source>Am J Physiology-Renal Physiol</source><year>2011</year><volume>300</volume><issue>2</issue><fpage>F301</fpage><lpage>10</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1152/ajprenal.00607.2010</pub-id><pub-id pub-id-type="pmid">21147843</pub-id></element-citation><mixed-citation id="mc-CR58" publication-type="journal">Tesch GH, Lim AK-H. Recent insights into diabetic renal injury from the db/db mouse model of type 2 diabetic nephropathy. Am J Physiology-Renal Physiol. 2011;300(2):F301&#8211;10.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1152/ajprenal.00607.2010</pub-id><pub-id pub-id-type="pmid">21147843</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR59"><label>59.</label><citation-alternatives><element-citation id="ec-CR59" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cohen</surname><given-names>M</given-names></name><name name-style="western"><surname>Clements</surname><given-names>R</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>J</given-names></name><name name-style="western"><surname>Shearman</surname><given-names>C</given-names></name></person-group><article-title>Prevention of decline in renal function in the diabetic db/db mouse</article-title><source>Diabetologia</source><year>1996</year><volume>39</volume><fpage>270</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">8721771</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/BF00418341</pub-id></element-citation><mixed-citation id="mc-CR59" publication-type="journal">Cohen M, Clements R, Cohen J, Shearman C. Prevention of decline in renal function in the diabetic db/db mouse. Diabetologia. 1996;39:270&#8211;4.<pub-id pub-id-type="pmid">8721771</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/BF00418341</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR60"><label>60.</label><citation-alternatives><element-citation id="ec-CR60" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>H</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>M-z</given-names></name><name name-style="western"><surname>Takahashi</surname><given-names>T</given-names></name><name name-style="western"><surname>Fogo</surname><given-names>AB</given-names></name><etal/></person-group><article-title>Endothelial nitric oxide synthase deficiency produces accelerated nephropathy in diabetic mice</article-title><source>J Am Soc Nephrol</source><year>2006</year><volume>17</volume><issue>10</issue><fpage>2664</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">16971655</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1681/ASN.2006070798</pub-id><pub-id pub-id-type="pmcid">PMC4618687</pub-id></element-citation><mixed-citation id="mc-CR60" publication-type="journal">Zhao HJ, Wang S, Cheng H, Zhang M-z, Takahashi T, Fogo AB, et al. Endothelial nitric oxide synthase deficiency produces accelerated nephropathy in diabetic mice. J Am Soc Nephrol. 2006;17(10):2664&#8211;9.<pub-id pub-id-type="pmid">16971655</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1681/ASN.2006070798</pub-id><pub-id pub-id-type="pmcid">PMC4618687</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR61"><label>61.</label><citation-alternatives><element-citation id="ec-CR61" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Z</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Overstreet</surname><given-names>JM</given-names></name><name name-style="western"><surname>Chung</surname><given-names>S</given-names></name><name name-style="western"><surname>Niu</surname><given-names>A</given-names></name><name name-style="western"><surname>Fan</surname><given-names>X</given-names></name><etal/></person-group><article-title>Inhibition of epidermal growth factor receptor activation is associated with improved diabetic nephropathy and insulin resistance in type 2 diabetes</article-title><source>Diabetes</source><year>2018</year><volume>67</volume><issue>9</issue><fpage>1847</fpage><lpage>57</lpage><pub-id pub-id-type="pmid">29959129</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/db17-1513</pub-id><pub-id pub-id-type="pmcid">PMC6110321</pub-id></element-citation><mixed-citation id="mc-CR61" publication-type="journal">Li Z, Li Y, Overstreet JM, Chung S, Niu A, Fan X, et al. Inhibition of epidermal growth factor receptor activation is associated with improved diabetic nephropathy and insulin resistance in type 2 diabetes. Diabetes. 2018;67(9):1847&#8211;57.<pub-id pub-id-type="pmid">29959129</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/db17-1513</pub-id><pub-id pub-id-type="pmcid">PMC6110321</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR62"><label>62.</label><mixed-citation publication-type="other">Ingalls AM, Dickie MM, Shell G. Obese, a new mutation in the house mouse. 1950.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/oxfordjournals.jhered.a106073</pub-id><pub-id pub-id-type="pmid">14824537</pub-id></mixed-citation></ref><ref id="CR63"><label>63.</label><mixed-citation publication-type="other">Coleman DL. Obese and diabetes: two mutant genes causing diabetes-obesity syndromes in mice. Diabetologia. 1978;14:294&#8211;8.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/BF00429772</pub-id><pub-id pub-id-type="pmid">350680</pub-id></mixed-citation></ref><ref id="CR64"><label>64.</label><citation-alternatives><element-citation id="ec-CR64" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Suriano</surname><given-names>F</given-names></name><name name-style="western"><surname>Vieira-Silva</surname><given-names>S</given-names></name><name name-style="western"><surname>Falony</surname><given-names>G</given-names></name><name name-style="western"><surname>Roumain</surname><given-names>M</given-names></name><name name-style="western"><surname>Paquot</surname><given-names>A</given-names></name><name name-style="western"><surname>Pelicaen</surname><given-names>R</given-names></name><etal/></person-group><article-title>Novel insights into the genetically obese (ob/ob) and diabetic (db/db) mice: two sides of the same coin</article-title><source>Microbiome</source><year>2021</year><volume>9</volume><fpage>1</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">34183063</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40168-021-01097-8</pub-id><pub-id pub-id-type="pmcid">PMC8240277</pub-id></element-citation><mixed-citation id="mc-CR64" publication-type="journal">Suriano F, Vieira-Silva S, Falony G, Roumain M, Paquot A, Pelicaen R, et al. Novel insights into the genetically obese (ob/ob) and diabetic (db/db) mice: two sides of the same coin. Microbiome. 2021;9:1&#8211;20.<pub-id pub-id-type="pmid">34183063</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40168-021-01097-8</pub-id><pub-id pub-id-type="pmcid">PMC8240277</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR65"><label>65.</label><citation-alternatives><element-citation id="ec-CR65" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clee</surname><given-names>SM</given-names></name><name name-style="western"><surname>Nadler</surname><given-names>ST</given-names></name><name name-style="western"><surname>Attie</surname><given-names>AD</given-names></name></person-group><article-title>Genetic and genomic studies of the BTBR ob/ob mouse model of type 2 diabetes</article-title><source>Am J Ther</source><year>2005</year><volume>12</volume><issue>6</issue><fpage>491</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">16280642</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/01.mjt.0000178781.89789.25</pub-id></element-citation><mixed-citation id="mc-CR65" publication-type="journal">Clee SM, Nadler ST, Attie AD. Genetic and genomic studies of the BTBR ob/ob mouse model of type 2 diabetes. Am J Ther. 2005;12(6):491&#8211;8.<pub-id pub-id-type="pmid">16280642</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/01.mjt.0000178781.89789.25</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR66"><label>66.</label><citation-alternatives><element-citation id="ec-CR66" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clee</surname><given-names>SM</given-names></name><name name-style="western"><surname>Attie</surname><given-names>AD</given-names></name></person-group><article-title>The genetic landscape of type 2 diabetes in mice</article-title><source>Endocr Rev</source><year>2007</year><volume>28</volume><issue>1</issue><fpage>48</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">17018838</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/er.2006-0035</pub-id></element-citation><mixed-citation id="mc-CR66" publication-type="journal">Clee SM, Attie AD. The genetic landscape of type 2 diabetes in mice. Endocr Rev. 2007;28(1):48&#8211;83.<pub-id pub-id-type="pmid">17018838</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/er.2006-0035</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR67"><label>67.</label><citation-alternatives><element-citation id="ec-CR67" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hudkins</surname><given-names>KL</given-names></name><name name-style="western"><surname>Pichaiwong</surname><given-names>W</given-names></name><name name-style="western"><surname>Wietecha</surname><given-names>T</given-names></name><name name-style="western"><surname>Kowalewska</surname><given-names>J</given-names></name><name name-style="western"><surname>Banas</surname><given-names>MC</given-names></name><name name-style="western"><surname>Spencer</surname><given-names>MW</given-names></name><etal/></person-group><article-title>BTBR ob/ob mutant mice model progressive diabetic nephropathy</article-title><source>J Am Soc Nephrol</source><year>2010</year><volume>21</volume><issue>9</issue><fpage>1533</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">20634301</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1681/ASN.2009121290</pub-id><pub-id pub-id-type="pmcid">PMC3013527</pub-id></element-citation><mixed-citation id="mc-CR67" publication-type="journal">Hudkins KL, Pichaiwong W, Wietecha T, Kowalewska J, Banas MC, Spencer MW, et al. BTBR ob/ob mutant mice model progressive diabetic nephropathy. J Am Soc Nephrol. 2010;21(9):1533&#8211;42.<pub-id pub-id-type="pmid">20634301</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1681/ASN.2009121290</pub-id><pub-id pub-id-type="pmcid">PMC3013527</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR68"><label>68.</label><citation-alternatives><element-citation id="ec-CR68" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hudkins</surname><given-names>KL</given-names></name><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><name name-style="western"><surname>Holland</surname><given-names>AL</given-names></name><name name-style="western"><surname>Swaminathan</surname><given-names>S</given-names></name><name name-style="western"><surname>Alpers</surname><given-names>CE</given-names></name></person-group><article-title>Regression of diabetic nephropathy by treatment with empagliflozin in BTBR ob/ob mice</article-title><source>Nephrol Dialysis Transplantation</source><year>2022</year><volume>37</volume><issue>5</issue><fpage>847</fpage><lpage>59</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ndt/gfab330</pub-id><pub-id pub-id-type="pmid">34865099</pub-id></element-citation><mixed-citation id="mc-CR68" publication-type="journal">Hudkins KL, Li X, Holland AL, Swaminathan S, Alpers CE. Regression of diabetic nephropathy by treatment with empagliflozin in BTBR ob/ob mice. Nephrol Dialysis Transplantation. 2022;37(5):847&#8211;59.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ndt/gfab330</pub-id><pub-id pub-id-type="pmid">34865099</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR69"><label>69.</label><citation-alternatives><element-citation id="ec-CR69" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Betz</surname><given-names>B</given-names></name><name name-style="western"><surname>Conway</surname><given-names>BR</given-names></name></person-group><article-title>An update on the use of animal models in diabetic nephropathy research</article-title><source>Curr Diab Rep</source><year>2016</year><volume>16</volume><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">26814757</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11892-015-0706-2</pub-id><pub-id pub-id-type="pmcid">PMC4729785</pub-id></element-citation><mixed-citation id="mc-CR69" publication-type="journal">Betz B, Conway BR. An update on the use of animal models in diabetic nephropathy research. Curr Diab Rep. 2016;16:1&#8211;9.<pub-id pub-id-type="pmid">26814757</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11892-015-0706-2</pub-id><pub-id pub-id-type="pmcid">PMC4729785</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR70"><label>70.</label><citation-alternatives><element-citation id="ec-CR70" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tomino</surname><given-names>Y</given-names></name></person-group><article-title>Lessons from the KK-Ay mouse, a spontaneous animal model for the treatment of human type 2 diabetic nephropathy</article-title><source>Nephro-urology Monthly</source><year>2012</year><volume>4</volume><issue>3</issue><fpage>524</fpage><pub-id pub-id-type="pmid">23573479</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5812/numonthly.1954</pub-id><pub-id pub-id-type="pmcid">PMC3614295</pub-id></element-citation><mixed-citation id="mc-CR70" publication-type="journal">Tomino Y. Lessons from the KK-Ay mouse, a spontaneous animal model for the treatment of human type 2 diabetic nephropathy. Nephro-urology Monthly. 2012;4(3):524.<pub-id pub-id-type="pmid">23573479</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5812/numonthly.1954</pub-id><pub-id pub-id-type="pmcid">PMC3614295</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR71"><label>71.</label><citation-alternatives><element-citation id="ec-CR71" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ito</surname><given-names>T</given-names></name><name name-style="western"><surname>Tanimoto</surname><given-names>M</given-names></name><name name-style="western"><surname>Yamada</surname><given-names>K</given-names></name><name name-style="western"><surname>Kaneko</surname><given-names>S</given-names></name><name name-style="western"><surname>Matsumoto</surname><given-names>M</given-names></name><name name-style="western"><surname>Obayashi</surname><given-names>K</given-names></name><etal/></person-group><article-title>Glomerular changes in the KK-Ay/Ta mouse: a possible model for human type 2 diabetic nephropathy</article-title><source>Nephrology</source><year>2006</year><volume>11</volume><issue>1</issue><fpage>29</fpage><lpage>35</lpage><pub-id pub-id-type="pmid">16509929</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1440-1797.2006.00543.x</pub-id></element-citation><mixed-citation id="mc-CR71" publication-type="journal">Ito T, Tanimoto M, Yamada K, Kaneko S, Matsumoto M, Obayashi K, et al. Glomerular changes in the KK-Ay/Ta mouse: a possible model for human type 2 diabetic nephropathy. Nephrology. 2006;11(1):29&#8211;35.<pub-id pub-id-type="pmid">16509929</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1440-1797.2006.00543.x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR72"><label>72.</label><citation-alternatives><element-citation id="ec-CR72" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Omote</surname><given-names>K</given-names></name><name name-style="western"><surname>Gohda</surname><given-names>T</given-names></name><name name-style="western"><surname>Murakoshi</surname><given-names>M</given-names></name><name name-style="western"><surname>Sasaki</surname><given-names>Y</given-names></name><name name-style="western"><surname>Kazuno</surname><given-names>S</given-names></name><name name-style="western"><surname>Fujimura</surname><given-names>T</given-names></name><etal/></person-group><article-title>Role of the TNF pathway in the progression of diabetic nephropathy in KK-Ay mice</article-title><source>Am J Physiology-Renal Physiol</source><year>2014</year><volume>306</volume><issue>11</issue><fpage>F1335</fpage><lpage>47</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1152/ajprenal.00509.2013</pub-id><pub-id pub-id-type="pmid">24647715</pub-id></element-citation><mixed-citation id="mc-CR72" publication-type="journal">Omote K, Gohda T, Murakoshi M, Sasaki Y, Kazuno S, Fujimura T, et al. Role of the TNF pathway in the progression of diabetic nephropathy in KK-Ay mice. Am J Physiology-Renal Physiol. 2014;306(11):F1335&#8211;47.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1152/ajprenal.00509.2013</pub-id><pub-id pub-id-type="pmid">24647715</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR73"><label>73.</label><citation-alternatives><element-citation id="ec-CR73" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name></person-group><article-title>Effects of chronic administration of alogliptin on the development of diabetes and &#946;-cell function in high fat diet/streptozotocin diabetic mice</article-title><source>Diabetes Obes Metabolism</source><year>2011</year><volume>13</volume><issue>4</issue><fpage>337</fpage><lpage>47</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1463-1326.2010.01354.x</pub-id><pub-id pub-id-type="pmid">21205126</pub-id></element-citation><mixed-citation id="mc-CR73" publication-type="journal">Zhang X, Wang Z, Huang Y, Wang J. Effects of chronic administration of alogliptin on the development of diabetes and &#946;-cell function in high fat diet/streptozotocin diabetic mice. Diabetes Obes Metabolism. 2011;13(4):337&#8211;47.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1463-1326.2010.01354.x</pub-id><pub-id pub-id-type="pmid">21205126</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR74"><label>74.</label><citation-alternatives><element-citation id="ec-CR74" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deng</surname><given-names>X</given-names></name><name name-style="western"><surname>Sun</surname><given-names>L</given-names></name><name name-style="western"><surname>Lai</surname><given-names>X</given-names></name><name name-style="western"><surname>Xiang</surname><given-names>L</given-names></name><name name-style="western"><surname>Li</surname><given-names>Q</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W</given-names></name><etal/></person-group><article-title>Tea polypeptide ameliorates diabetic nephropathy through RAGE and NF-&#954;B signaling pathway in type 2 diabetes mice</article-title><source>J Agric Food Chem</source><year>2018</year><volume>66</volume><issue>45</issue><fpage>11957</fpage><lpage>67</lpage><pub-id pub-id-type="pmid">30354109</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.jafc.8b04819</pub-id></element-citation><mixed-citation id="mc-CR74" publication-type="journal">Deng X, Sun L, Lai X, Xiang L, Li Q, Zhang W, et al. Tea polypeptide ameliorates diabetic nephropathy through RAGE and NF-&#954;B signaling pathway in type 2 diabetes mice. J Agric Food Chem. 2018;66(45):11957&#8211;67.<pub-id pub-id-type="pmid">30354109</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.jafc.8b04819</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR75"><label>75.</label><citation-alternatives><element-citation id="ec-CR75" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></name><name name-style="western"><surname>Tao</surname><given-names>H</given-names></name><name name-style="western"><surname>Xu</surname><given-names>N</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>S</given-names></name><name name-style="western"><surname>Peng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>J</given-names></name><etal/></person-group><article-title>Chrysin improves diabetic nephropathy by regulating the AMPK-mediated lipid metabolism in HFD/STZ&#8208;induced DN mice</article-title><source>J Food Biochem</source><year>2022</year><volume>46</volume><issue>12</issue><fpage>e14379</fpage><pub-id pub-id-type="pmid">35976957</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jfbc.14379</pub-id></element-citation><mixed-citation id="mc-CR75" publication-type="journal">Zhou Y, Tao H, Xu N, Zhou S, Peng Y, Zhu J, et al. Chrysin improves diabetic nephropathy by regulating the AMPK-mediated lipid metabolism in HFD/STZ&#8208;induced DN mice. J Food Biochem. 2022;46(12):e14379.<pub-id pub-id-type="pmid">35976957</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jfbc.14379</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR76"><label>76.</label><citation-alternatives><element-citation id="ec-CR76" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Hou</surname><given-names>J-g</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Gong</surname><given-names>X-j</given-names></name><name name-style="western"><surname>Hu</surname><given-names>J-n</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y-p</given-names></name><etal/></person-group><article-title>Alleviative effects of 20 (R)-Rg3 on HFD/STZ-induced diabetic nephropathy via MAPK/NF-&#954;B signaling pathways in C57BL/6 mice</article-title><source>J Ethnopharmacol</source><year>2021</year><volume>267</volume><fpage>113500</fpage><pub-id pub-id-type="pmid">33091499</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jep.2020.113500</pub-id></element-citation><mixed-citation id="mc-CR76" publication-type="journal">Li Y, Hou J-g, Liu Z, Gong X-j, Hu J-n, Wang Y-p, et al. Alleviative effects of 20 (R)-Rg3 on HFD/STZ-induced diabetic nephropathy via MAPK/NF-&#954;B signaling pathways in C57BL/6 mice. J Ethnopharmacol. 2021;267:113500.<pub-id pub-id-type="pmid">33091499</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jep.2020.113500</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR77"><label>77.</label><citation-alternatives><element-citation id="ec-CR77" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>R</given-names></name><name name-style="western"><surname>Dong</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>D</given-names></name><name name-style="western"><surname>Gu</surname><given-names>Y</given-names></name></person-group><article-title>Female mouse model of diabetes mellitus induced by streptozotocin and high-carbohydrate high-fat diet</article-title><source>Pol J Vet Sci</source><year>2022</year><volume>547</volume><fpage>55</fpage><lpage>55</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.24425/pjvs.2022.142042</pub-id><pub-id pub-id-type="pmid">36649103</pub-id></element-citation><mixed-citation id="mc-CR77" publication-type="journal">Guo R, Dong J, Wang D, Gu Y. Female mouse model of diabetes mellitus induced by streptozotocin and high-carbohydrate high-fat diet. Pol J Vet Sci. 2022;547:55&#8211;55.<pub-id pub-id-type="doi" assigning-authority="pmc">10.24425/pjvs.2022.142042</pub-id><pub-id pub-id-type="pmid">36649103</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR78"><label>78.</label><citation-alternatives><element-citation id="ec-CR78" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hartono</surname><given-names>SP</given-names></name><name name-style="western"><surname>Knudsen</surname><given-names>BE</given-names></name><name name-style="western"><surname>Lerman</surname><given-names>LO</given-names></name><name name-style="western"><surname>Textor</surname><given-names>SC</given-names></name><name name-style="western"><surname>Grande</surname><given-names>JP</given-names></name></person-group><article-title>Combined effect of hyperfiltration and Renin angiotensin system activation on development of chronic kidney disease in diabetic db/db mice</article-title><source>BMC Nephrol</source><year>2014</year><volume>15</volume><fpage>1</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">24708836</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1471-2369-15-58</pub-id><pub-id pub-id-type="pmcid">PMC3984262</pub-id></element-citation><mixed-citation id="mc-CR78" publication-type="journal">Hartono SP, Knudsen BE, Lerman LO, Textor SC, Grande JP. Combined effect of hyperfiltration and Renin angiotensin system activation on development of chronic kidney disease in diabetic db/db mice. BMC Nephrol. 2014;15:1&#8211;14.<pub-id pub-id-type="pmid">24708836</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1471-2369-15-58</pub-id><pub-id pub-id-type="pmcid">PMC3984262</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR79"><label>79.</label><citation-alternatives><element-citation id="ec-CR79" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kashyap</surname><given-names>S</given-names></name><name name-style="western"><surname>Engel</surname><given-names>S</given-names></name><name name-style="western"><surname>Osman</surname><given-names>M</given-names></name><name name-style="western"><surname>Al-Saiegh</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wongjarupong</surname><given-names>A</given-names></name><name name-style="western"><surname>Grande</surname><given-names>JP</given-names></name></person-group><article-title>Cardiovascular manifestations of renovascular hypertension in diabetic mice</article-title><source>PeerJ</source><year>2016</year><volume>4</volume><fpage>e1736</fpage><pub-id pub-id-type="pmid">26925344</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7717/peerj.1736</pub-id><pub-id pub-id-type="pmcid">PMC4768709</pub-id></element-citation><mixed-citation id="mc-CR79" publication-type="journal">Kashyap S, Engel S, Osman M, Al-Saiegh Y, Wongjarupong A, Grande JP. Cardiovascular manifestations of renovascular hypertension in diabetic mice. PeerJ. 2016;4:e1736.<pub-id pub-id-type="pmid">26925344</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7717/peerj.1736</pub-id><pub-id pub-id-type="pmcid">PMC4768709</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR80"><label>80.</label><citation-alternatives><element-citation id="ec-CR80" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Caramori</surname><given-names>ML</given-names></name><name name-style="western"><surname>Fioretto</surname><given-names>P</given-names></name><name name-style="western"><surname>Mauer</surname><given-names>M</given-names></name></person-group><article-title>The need for early predictors of diabetic nephropathy risk: is albumin excretion rate sufficient?</article-title><source>Diabetes</source><year>2000</year><volume>49</volume><issue>9</issue><fpage>1399</fpage><lpage>408</lpage><pub-id pub-id-type="pmid">10969821</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/diabetes.49.9.1399</pub-id></element-citation><mixed-citation id="mc-CR80" publication-type="journal">Caramori ML, Fioretto P, Mauer M. The need for early predictors of diabetic nephropathy risk: is albumin excretion rate sufficient? Diabetes. 2000;49(9):1399&#8211;408.<pub-id pub-id-type="pmid">10969821</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/diabetes.49.9.1399</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR81"><label>81.</label><citation-alternatives><element-citation id="ec-CR81" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sundberg</surname><given-names>JP</given-names></name><name name-style="western"><surname>Schofield</surname><given-names>PN</given-names></name></person-group><article-title>Living inside the box: environmental effects on mouse models of human disease</article-title><source>Dis Models Mech</source><year>2018</year><volume>11</volume><issue>10</issue><fpage>dmm035360</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1242/dmm.035360</pub-id><pub-id pub-id-type="pmcid">PMC6215423</pub-id><pub-id pub-id-type="pmid">30194139</pub-id></element-citation><mixed-citation id="mc-CR81" publication-type="journal">Sundberg JP, Schofield PN. Living inside the box: environmental effects on mouse models of human disease. Dis Models Mech. 2018;11(10):dmm035360.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1242/dmm.035360</pub-id><pub-id pub-id-type="pmcid">PMC6215423</pub-id><pub-id pub-id-type="pmid">30194139</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>